Eosinophilic Esophagitis
Conditions
Keywords
Esophagitis, Eosinophilic Esophagitis, Fluticasone, Dysphagia, Safety, Efficacy, Pharmacokinetics, Esophageal Diseases, Gastrointestinal Diseases, Digestive System Diseases, Glucocorticoids, Orally Disintegrating Tablet
Brief summary
Eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus, characterized by eosinophilic infiltration and gastrointestinal symptoms. Swallowed, topically acting corticosteroids, such as fluticasone, appear to be effective in resolving acute clinical and pathological features of EoE. APT-1011 is an orally disintegrating tablet (ODT) formulation of fluticasone propionate. This study is designed to compare the efficacy and safety of APT-1011 with placebo in adults with EoE for an initial 12-week treatment period, followed by an additional 40-week maintenance treatment phase. Histologic response, pharmacokinetics, and dysphagia will be assessed.
Detailed description
FLUTE is a phase 2b randomized, double-blind, placebo-controlled dose-ranging clinical trial of APT-1011 versus placebo in 100 adult subjects (≥18 years of age) diagnosed with EoE. Efficacy (including histologic, endoscopic, and symptomatic response), safety, and PK of APT-1011 will be examined. Participants will be given an electronic diary to record symptoms and medication intake daily. FLUTE will be conducted in several parts (Screening \[4 weeks\], followed by a 4-week Baseline Symptom Assessment, and 2 treatment parts \[Part 1: 14-week Induction and Part 2: 38-week Maintenance\]), with a follow-up visit to occur 2 weeks after the final dose of study drug. In Part 1 of the study, approximately 100 subjects will be randomized 1:1:1:1:1 to receive placebo or one of 4 active doses of APT-1011. All subjects will receive one tablet 30 minutes after breakfast and one tablet at bedtime (HS). The dosing groups include: 1.5 mg HS APT-1011, 1.5 mg twice daily (BID) (total daily dose of 3 mg) APT-1011, 3 mg HS APT-1011, and 3 mg BID (total daily dose of 6 mg) APT-1011, and placebo BID. In Part 2, all subjects classified as histologic responders at Week 12 will continue to be treated according to the dosing group to which they were randomized, and non-responders will receive single-blind 3 mg BID. All subjects who are histologic non-responders at Week 26 will stop treatment at Week 28 and enter the 2-week follow-up and exit the study. Histologic responders at Week 26 will continue on the same dose until end-of-study at Week 52. Subjects will complete a follow-up visit 2 weeks after the final dose of study drug. All subjects must have a final EGD within 3 weeks prior to completing the Follow-up Visit unless the subject withdraws consent or has a contraindication to EGD.
Interventions
DRUGAPT-1011
APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate
DRUGPlacebo
Placebo tablets are identical in composition to APT-1011 except they exclude the active ingredient.
Sponsors
Adare Pharmaceuticals, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Double Blind
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Male or female between ≥18 and ≤75 years of age at the time of informed consent * Signed informed consent * Evidence of EoE defined by ≥15 peak eosinophils per HPF as measured from proximal and distal biopsies * Subject-reported history of ≥3 episodes of dysphagia in the 7 days prior to Screening * 7-day Global EoE Symptom Score \>3 at baseline and at screening * Willing and able to adhere to study-related treatment regimens, procedures, and visit schedule
Exclusion criteria
* Have known contraindication, hypersensitivity, or intolerance to corticosteroids; * Have any physical, mental, or social condition or history of illness or laboratory abnormality that in the Investigator's judgment might interfere with study procedures or the ability of the subject to adhere to and complete the study; * Presence of oral or esophageal mucosal infection of any type; * Have any mouth or dental condition that prevents normal eating; * Have any condition affecting the esophageal mucosa or altering esophageal motility other than EoE; * Use of systemic corticosteroids within 60 days prior to Screening, use of inhaled/swallowed corticosteroids within 30 days prior to Screening, or extended use of high-potency dermal topical corticosteroids within 30 days prior to Screening; * Initiation of an elimination diet or elemental diet within 30 days before Screening (diet must remain stable after signing ICF); * Morning serum cortisol level ≤5 μg/dL (138 nmol/L); * Use of biologic immunomodulators in the 24 weeks prior to Screening; * Use of calcineurin inhibitors or purine analogues, or potent cytochrome P450 (CYP) 3A4 inhibitors in the 12 weeks prior to Screening; * Have a contraindication to or factors that substantially increase the risk of EGD or esophageal biopsy or have narrowing of the esophagus that precludes EGD with a standard 9 mm endoscope; * Have a history of an esophageal stricture requiring dilatation within the previous 12 weeks prior to Screening; * Have initiated, discontinued or changed dosage regimen of PPIs, H2 antagonists, antacids or antihistamines for any condition such as GERD or allergic rhinitis within 4 weeks prior to qualifying endoscopy. These drugs must remain constant throughout the study. * A serum cortisol level \<18 μg/dL (497 nmol/L) at 60 minutes with adrenocorticotropic hormone (ACTH) stimulation test using 250 μg cosyntropin (i.e., a positive result on the ACTH stimulation test).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Subjects With ≤6 Peak Eosinophils/High-power Field (HPF) | Week 12 | Histology (eosinophils per high power field \[HPF\]): percentage of subjects with ≤6 PEAK eosinophils/HPF after assessing at least 5-6 biopsies from the proximal and distal esophagus (\ 3 each) where the HPF area is 235 square microns (40 magnification lens with a 22 mm ocular). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Total Score | Weeks 12, 26 and 52 | Change from Baseline 7-Day EEsAI total score assessed prior to randomization and those assessed at Weeks 12, 26 and 52 (Total score 100). Eosinophilic Esophagitis Activity Index Total Score: 0 (best) to 100 (worst) based on the sum of the categorized subscores for frequency of trouble swallowing \[never (0), 1-3x (15) or 4-6x (27) per week\]; duration of trouble swallowing \[≤5 min (0), \>5 min (6)\]; pain when swallowing \[no (0), yes (15)\]; Visual Dysphagia Question score \[0 (best),12,19, 21, or 23 (worst)\]; avoidance modification and slow eating score \[0 (best), 9, or 25 (worst)\]. A higher score means a worse outcome. Population used are those who entered Part 1 - Induction. The number of participants analyzed for each timepoint reflect the actual number of participants with data at that timepoint. Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect the change from baseline 7-day EEs |
| Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Weeks 4, 8, 12, 14, 18, 22, 26, 36, 44, and 52 | Change From Baseline PGIC for EoE Symptoms as Assessed Prior to Randomization at Weeks 4, 8, 12, 14, 18, 22, 26, 28, 36, 44, and 52. Population used are those who entered Part 1 - Induction. The number of participants analyzed for each timepoint reflect the actual number of participants with data at that timepoint. Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect change from baseline PGIC for EoE symptoms following 4, 8, 12, 14, 22, 30 or 38 weeks of treatment. |
| Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Weeks 4, 8, 12, 14, 18, 22, 26, 36, 44, and 52 | Change From Baseline PGIC of Difficulty with Food or Pills as Assessed Prior to Randomization at Weeks 4, 8, 12, 14, 18, 22, 26, 28, 36, 44, and 52. Population used are those who entered Part 1 - Induction. The number of participants analyzed for each timepoint reflect the actual number of participants with data at that timepoint. Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect change from baseline PGIC of difficulty with food or pills following 4, 8, 12, 14, 22, 30 or 38 weeks of treatment. |
| Percentage of Histologic Non-responders by Dose at Weeks 12, 26, and 52 | Weeks 12, 26 and 52 | Percentage of histologic non-responders by dose at Weeks 12, 26, and 52. Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect non-response following 12 or 38 weeks of treatment. |
| Percentage of Subjects Requiring Emergency Endoscopic Food Dis-impaction | before Week 14, between Week 14 and Week 28, between Week 28 and Week 52 | Percentage of subjects requiring emergency endoscopic food dis-impaction by dose before Week 14, between Week 14 and Week 28, and between Week 28 and Week 52. Note: There were no patients in the placebo group after Week 14. |
| Percentage of Subjects Requiring Esophageal Dilation | baseline to Week 52 | Percentage of subjects requiring esophageal dilation by dosing group and part of the study. Note: There were no patients in the placebo group after Week 14. |
| Percentage of Subjects Who Met the Primary Endpoint at Week 12 and Maintained the Primary Endpoint at Weeks 26 and 52 | Week 26, and Week 52 | Percentage of subjects who entered Part 2 - Maintenance and met the primary endpoint (histology) at Week 12 and maintained the primary endpoint at Week 26 and Week 52. Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect percentage of subjects who met the primary endpoint following 12 or 38 weeks of treatment. |
| Change From Baseline Eosinophilic Esophagitis Endoscopic Reference Score (EREFs) at Week 12, 26, and 52 | Week 12, Week 26, and Week 52 | Endoscopic changes will be assessed as per the EREFs evaluation based on the following endoscopic features: edema \[Grade {Gr} 0 (absent) or Gr 1 (present)\], strictures \[Gr 0 (absent) or Gr 1 (present)\], rings \[Gr 0 (none), Gr 1 (mild), Gr 2 (moderate), Gr 3 (severe)\], exudates \[Gr 0 (none), Gr 1 (mild), Gr (severe)\], furrows \[Gr 0 (none), Gr 1 (mild), Gr 2 (severe)\], crepe paper esophagus \[Gr 0 (absent) or Gr 1 (present)\], narrow caliber esophagus \[Gr 0 (absent) or Gr 1 (present)\], and esophageal erosions \[Normal (0), Gr A (1), Gr B (2), Gr C (3), or Gr D (4)\]. EREFs: 0 (best) to 15 (worst) based on the sum of the subscores listed above. Population used are those who entered Part 1 - Induction. The number of participants analyzed for each timepoint reflect the actual number of participants with data at that timepoint. Note: Following Week 14, all patients in the placebo group were given APT-1011 3 mg BID and results reflect EREF evaluation following 12 or 38 weeks of treatment. |
| Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15 | Week 12, Week 26, and Week 52 | Percentage of subjects with a peak eosinophils/HPF \<1 and \<15 at Week 12, 26 and 52. Population used are those who entered Part 1 - Induction. The number of participants analyzed for each timepoint reflect the actual number of participants with data at that timepoint. Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect peak eosinophils/HPF following 12 or 38 weeks of treatment. |
| Change From Baseline Global EoE Symptom Score | Week 4, 8, 12, 14, 18, 22, 26, 28, 36, 44, and 52 | Change from baseline global EOE symptom score assessed prior to randomization to scores for 7-day recall at Week 4, 8, 12, 14, 18, 22, 26, 28, 36, 44, and 52 visits. Global Eosinophilic Esophagitis Symptom Score: On a scale from 0 (no symptoms) to 10 (most severe symptoms), how severe were your EoE symptoms over the past 7 days? Patients were asked to think of all their symptoms due to EoE and make an overall statement by selecting a number. Population used are those who entered Part 1 - Induction. The number of participants analyzed for each timepoint reflect the actual number of participants with data at that timepoint. Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect change from baseline global EOE symptom score following 4, 8, 12, 14, 22, 30 or 38 weeks of treatment. |
| Change in the Number of Dysphagia Episodes | Week 12, Week 26 and Week 52 | Change in the number of dysphagia episodes at baseline (14-day period prior to randomization) compared with the 14-day period prior to the time point of interest. Population used are those who entered Part 1 - Induction. The number of participants analyzed for each timepoint reflect the actual number of participants with data at that timepoint. Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect the change in the number of dysphagia episodes following 12 or 38 weeks of treatment. |
| Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores | Weeks 12, 26 and 52 | The Avoidance, Modification and Slow Eating (AMS) Score and Visual Dysphagia Question (VDQ) Score are components of the EEsAI. AMS: Answers to three items determining the pattern of behavioral adaptation were scored for each food consistency consumed by the subject (avoidance, modification, and eating slowly). The AMS score ranges from 0 (best) to 25 (worst). VDG: The degree of perceived difficulty when eating 8 different food consistencies was assessed. The VDQ score ranges from 0 (best) to 23 (worst). A higher score for either subscore means a worse outcome. Negative change from baseline represents a worsening in quality of life for the total score or subscore. Population used are those who entered Part 1 - Induction. The number of participants analyzed for each timepoint reflect the actual number of participants with data at that timepoint. Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect change from baseline. |
| Percentage of Subjects With Mean 7-day EEsAI Total Score <20 | Weeks 12, 26, and 52 | Percentage of subjects with mean 7-day EEsAI total score \<20 to those assessed at Weeks 12, 26 and 52. Eosinophilic Esophagitis Activity Index Total Score: 0 (best) to 100 (worst) based on the sum of the categorized subscores for frequency of trouble swallowing \[never (0), 1-3x (15) or 4-6x (27) per week\]; duration of trouble swallowing \[\<= 5 min (0), \>5 min (6)\]; pain when swallowing \[no (0), yes (15)\]; Visual Dysphagia Question score \[0 (best),12,19,21, or 23 (worst)\]; avoidance modification and slow eating score \[0 (best), 9, or 25 (worst)\]. Population used are those who entered Part 1 - Induction. The number of participants analyzed for each timepoint reflect the actual number of participants with data at that timepoint. Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect change from baseline global EOE symptom score following 12 or 38 weeks of treatment |
| Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Weeks 4, 8, 12, 14, 18, 22, 26, 28, 36, 44, and 52 | Change From Baseline PGIS for EoE Symptoms as Assessed Prior to Randomization at Weeks 4, 8, 12, 14, 18, 22, 26, 28, 36, 44, and 52. Population used are those who entered Part 1 - Induction. The number of participants analyzed for each timepoint reflect the actual number of participants with data at that timepoint. Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect change from baseline global EOE symptoms following 4, 8, 12, 14, 22, 30 or 38 weeks of treatment. |
| Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Weeks 4, 8, 12, 14, 18, 22, 26, 28, 36, 44, and 52 | Change From Baseline PGIS for Difficulty with Food or Pills Going Down as Assessed Prior to Randomization at Weeks 4, 8, 12, 14, 18, 22, 26, 28, 36, 44, and 52. Population used are those who entered Part 1 - Induction. The number of participants analyzed for each timepoint reflect the actual number of participants with data at that timepoint. Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect change from baseline PGIS for difficulty with food or pills going down following 4, 8, 12, 14, 22, 30 or 38 weeks of treatment. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects With Treatment-Emergent Adverse Events Leading to Study Discontinuation in Part 1 | baseline to Week 12 | Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) Leading to Study Discontinuation in Part 1. |
| Number of Subjects With Treatment-Emergent Adverse Events Leading to Study Discontinuation in Part 2 | Week 12 to 52 | Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) Leading to Study Discontinuation in Part 2. |
| Percentage of Subjects With Serum Cortisol Level ≤5 μg/dL or Abnormal Adrenocorticotropic Hormone (ACTH) Stimulation Test | Week 12 to 52 | Percentage of subjects with serum cortisol level ≤5 μg/dL (≤138 nmol/L) or abnormal adrenocorticotropic hormone (ACTH) stimulation test (serum cortisol \<16 μg/dL \[≤440 nmol/L\] at 60 minutes). Population used are those who entered Part 2 - Maintenance. The number of participants analyzed for each timepoint reflect the actual number of participants with data at that timepoint. |
| Number of Subjects With Oral and Esophageal Candidiasis | baseline to Week 52 | Frequency of oral and esophageal candidiasis. Note: There were no patients in the placebo group after Week 14. |
| Number of Subjects Discontinuing Due to HPA Axis Suppression | baseline to Week 52 | Number of subjects discontinuing due to HPA axis suppression. Note: There were no patients in the placebo group after Week 14. |
Countries
Belgium, Canada, Germany, Spain, Switzerland, United States
Participant flow
Recruitment details
Recruitment in 6 countries (United States, Canada, Belgium, Germany, Spain, and Switzerland) took place between 22-Jun-2017 (First Subject Enrolled) until 23-Aug-2018 (Last Subject Enrolled).
Pre-assignment details
The Screening Period was 4 weeks (28 days) and utilized a single-blind placebo run-in period. Along with the reports confirming the subject's primary diagnosis of EoE, the Investigator assessed eligibility criteria of the subject based on screening results. The Global EoE Symptom Score had to be \>3 for the subject to continue in the study. Patients who were screened (308) are presented under Baseline Symptom Assessment, those enrolled (106) are presented in Part 1 - Induction.
Participants by arm
| Arm | Count |
|---|---|
| APT-1011 1.5 mg HS Placebo after breakfast, APT-1011 1.5 mg HS
APT-1011: APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate
Placebo: Placebo tablets are identical in composition to APT-1011 except they exclude the active ingredient. | 21 |
| APT-1011 1.5 mg BID APT-1011 1.5 mg after breakfast, APT-1011 1.5 mg HS
APT-1011: APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate | 22 |
| APT-1011 3 mg HS Placebo after breakfast, APT-1011 3 mg HS
APT-1011: APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate
Placebo: Placebo tablets are identical in composition to APT-1011 except they exclude the active ingredient. | 22 |
| APT-1011 3 mg BID APT-1011 3 mg after breakfast, APT-1011 3 mg HS
APT-1011: APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate | 20 |
| Placebo BID Placebo 30 minutes after breakfast and HS
Placebo: Placebo tablets are identical in composition to APT-1011 except they exclude the active ingredient. | 21 |
| Total | 106 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Baseline Symptom Assessment | Adverse Event | 0 | 0 | 0 | 0 | 0 | 2 |
| Baseline Symptom Assessment | Lost to Follow-up | 0 | 0 | 0 | 0 | 0 | 1 |
| Baseline Symptom Assessment | Patient Diary Unavailable at Site | 0 | 0 | 0 | 0 | 0 | 1 |
| Baseline Symptom Assessment | Violation of inclusion/exclusion criteria | 0 | 0 | 0 | 0 | 0 | 179 |
| Baseline Symptom Assessment | Withdrawal by Subject | 0 | 0 | 0 | 0 | 0 | 19 |
| Part 1 - Induction | Adverse Event | 0 | 2 | 0 | 1 | 0 | 2 |
| Part 1 - Induction | Randomized but never dosed | 0 | 0 | 1 | 0 | 0 | 0 |
| Part 1 - Induction | Violation of inclusion/exclusion criteria | 0 | 0 | 1 | 0 | 0 | 1 |
| Part 1 - Induction | Withdrawal by Subject | 3 | 1 | 0 | 0 | 0 | 2 |
| Part 2 - Maintenance | Adverse Event | 0 | 0 | 0 | 0 | 1 | 0 |
| Part 2 - Maintenance | Lack of Efficacy | 1 | 2 | 2 | 2 | 10 | 0 |
| Part 2 - Maintenance | Physician Decision | 1 | 0 | 0 | 0 | 0 | 0 |
| Part 2 - Maintenance | Refused EGD at Week 26 | 0 | 0 | 1 | 0 | 0 | 0 |
| Part 2 - Maintenance | Subject Could Not Transfer Site to Complete the Study | 1 | 0 | 0 | 0 | 0 | 0 |
| Part 2 - Maintenance | Unresponsive - Patient missed multiple appointments | 0 | 0 | 0 | 0 | 1 | 0 |
| Part 2 - Maintenance | Withdrawal by Subject | 2 | 0 | 0 | 0 | 3 | 0 |
Baseline characteristics
| Characteristic | APT-1011 3 mg HS | APT-1011 1.5 mg HS | APT-1011 3 mg BID | APT-1011 1.5 mg BID | Placebo BID | Total |
|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 2 Participants |
| Age, Categorical Between 18 and 65 years | 21 Participants | 21 Participants | 20 Participants | 21 Participants | 21 Participants | 104 Participants |
| Age, Continuous | 41.9 years STANDARD_DEVIATION 12.09 | 36.8 years STANDARD_DEVIATION 11.65 | 36.8 years STANDARD_DEVIATION 9.19 | 41.3 years STANDARD_DEVIATION 12.24 | 38.7 years STANDARD_DEVIATION 13.94 | 39.2 years STANDARD_DEVIATION 11.92 |
| BMI | 28.68 kg/m^2 STANDARD_DEVIATION 6.74 | 28.27 kg/m^2 STANDARD_DEVIATION 5.19 | 25.54 kg/m^2 STANDARD_DEVIATION 4.45 | 27.39 kg/m^2 STANDARD_DEVIATION 4.34 | 28.02 kg/m^2 STANDARD_DEVIATION 6.53 | 27.60 kg/m^2 STANDARD_DEVIATION 5.57 |
| Current esophageal stricture(s) based on the study EGD Missing | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Current esophageal stricture(s) based on the study EGD No | 17 Participants | 17 Participants | 16 Participants | 17 Participants | 16 Participants | 83 Participants |
| Current esophageal stricture(s) based on the study EGD Yes | 5 Participants | 4 Participants | 4 Participants | 5 Participants | 5 Participants | 23 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants | 4 Participants | 2 Participants | 5 Participants | 3 Participants | 16 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 20 Participants | 17 Participants | 16 Participants | 17 Participants | 17 Participants | 87 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 1 Participants | 3 Participants |
| Global EOE Symptom Score prior to randomization | 5.00 units on a scale STANDARD_DEVIATION 1.95 | 5.14 units on a scale STANDARD_DEVIATION 1.62 | 4.25 units on a scale STANDARD_DEVIATION 1.94 | 4.50 units on a scale STANDARD_DEVIATION 2.13 | 4.95 units on a scale STANDARD_DEVIATION 1.66 | 4.77 units on a scale STANDARD_DEVIATION 1.87 |
| Height | 171.0 cm STANDARD_DEVIATION 9.62 | 175.4 cm STANDARD_DEVIATION 8.55 | 176.7 cm STANDARD_DEVIATION 8.61 | 173.0 cm STANDARD_DEVIATION 8.56 | 174.8 cm STANDARD_DEVIATION 7.2 | 174.1 cm STANDARD_DEVIATION 8.63 |
| History of esophageal stricture(s) Missing | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| History of esophageal stricture(s) No | 14 Participants | 10 Participants | 12 Participants | 12 Participants | 12 Participants | 60 Participants |
| History of esophageal stricture(s) Yes | 8 Participants | 11 Participants | 8 Participants | 10 Participants | 9 Participants | 46 Participants |
| History of positive steroid response to EOE Missing | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| History of positive steroid response to EOE No | 17 Participants | 18 Participants | 16 Participants | 17 Participants | 17 Participants | 85 Participants |
| History of positive steroid response to EOE Yes | 5 Participants | 3 Participants | 4 Participants | 5 Participants | 4 Participants | 21 Participants |
| Proton pump inhibitor status Continuing into study | 13 Participants | 12 Participants | 11 Participants | 16 Participants | 14 Participants | 66 Participants |
| Proton pump inhibitor status Missing | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Proton pump inhibitor status Not continuing into study | 9 Participants | 9 Participants | 9 Participants | 6 Participants | 7 Participants | 40 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 3 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 21 Participants | 21 Participants | 19 Participants | 22 Participants | 20 Participants | 103 Participants |
| Region of Enrollment Europe | 4 participants | 6 participants | 7 participants | 6 participants | 4 participants | 27 participants |
| Region of Enrollment North America | 18 participants | 15 participants | 13 participants | 16 participants | 17 participants | 79 participants |
| Sex: Female, Male Female | 10 Participants | 7 Participants | 4 Participants | 7 Participants | 5 Participants | 33 Participants |
| Sex: Female, Male Male | 12 Participants | 14 Participants | 16 Participants | 15 Participants | 16 Participants | 73 Participants |
| Smoking Status Current | 0 Participants | 1 Participants | 0 Participants | 2 Participants | 0 Participants | 3 Participants |
| Smoking Status Former | 3 Participants | 2 Participants | 4 Participants | 3 Participants | 4 Participants | 16 Participants |
| Smoking Status Missing | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Smoking Status Never | 19 Participants | 18 Participants | 16 Participants | 17 Participants | 17 Participants | 87 Participants |
| Weight | 83.47 kg STANDARD_DEVIATION 18.45 | 87.45 kg STANDARD_DEVIATION 17.69 | 79.72 kg STANDARD_DEVIATION 14.93 | 83.72 kg STANDARD_DEVIATION 14.72 | 85.45 kg STANDARD_DEVIATION 19.79 | 83.96 kg STANDARD_DEVIATION 17.09 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 21 | 0 / 23 | 0 / 21 | 0 / 20 | 0 / 20 | 0 / 10 | 0 / 19 | 0 / 14 | 0 / 16 | 0 / 34 | 0 / 50 |
| other Total, other adverse events | 13 / 21 | 17 / 23 | 16 / 21 | 17 / 20 | 13 / 20 | 7 / 10 | 14 / 19 | 13 / 14 | 12 / 16 | 22 / 34 | 34 / 50 |
| serious Total, serious adverse events | 0 / 21 | 0 / 23 | 1 / 21 | 0 / 20 | 0 / 20 | 1 / 10 | 0 / 19 | 1 / 14 | 0 / 16 | 0 / 34 | 0 / 50 |
Outcome results
Primary
Percentage of Subjects With ≤6 Peak Eosinophils/High-power Field (HPF)
Histology (eosinophils per high power field \[HPF\]): percentage of subjects with ≤6 PEAK eosinophils/HPF after assessing at least 5-6 biopsies from the proximal and distal esophagus (\ 3 each) where the HPF area is 235 square microns (40 magnification lens with a 22 mm ocular).
Time frame: Week 12
Population: Full Analysis Set Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| APT-1011 1.5 mg HS | Percentage of Subjects With ≤6 Peak Eosinophils/High-power Field (HPF) | Non-Responder | 11 Participants |
| APT-1011 1.5 mg HS | Percentage of Subjects With ≤6 Peak Eosinophils/High-power Field (HPF) | Responder | 10 Participants |
| APT-1011 1.5 mg BID | Percentage of Subjects With ≤6 Peak Eosinophils/High-power Field (HPF) | Responder | 19 Participants |
| APT-1011 1.5 mg BID | Percentage of Subjects With ≤6 Peak Eosinophils/High-power Field (HPF) | Non-Responder | 3 Participants |
| APT-1011 3 mg HS | Percentage of Subjects With ≤6 Peak Eosinophils/High-power Field (HPF) | Non-Responder | 7 Participants |
| APT-1011 3 mg HS | Percentage of Subjects With ≤6 Peak Eosinophils/High-power Field (HPF) | Responder | 14 Participants |
| APT-1011 3 mg BID | Percentage of Subjects With ≤6 Peak Eosinophils/High-power Field (HPF) | Responder | 16 Participants |
| APT-1011 3 mg BID | Percentage of Subjects With ≤6 Peak Eosinophils/High-power Field (HPF) | Non-Responder | 4 Participants |
| Placebo BID | Percentage of Subjects With ≤6 Peak Eosinophils/High-power Field (HPF) | Non-Responder | 19 Participants |
| Placebo BID | Percentage of Subjects With ≤6 Peak Eosinophils/High-power Field (HPF) | Responder | 0 Participants |
p-value: 0.001Cochran-Mantel-Haenszel
p-value: <0.001Cochran-Mantel-Haenszel
p-value: <0.001Cochran-Mantel-Haenszel
p-value: <0.001Cochran-Mantel-Haenszel
Secondary
Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores
The Avoidance, Modification and Slow Eating (AMS) Score and Visual Dysphagia Question (VDQ) Score are components of the EEsAI. AMS: Answers to three items determining the pattern of behavioral adaptation were scored for each food consistency consumed by the subject (avoidance, modification, and eating slowly). The AMS score ranges from 0 (best) to 25 (worst). VDG: The degree of perceived difficulty when eating 8 different food consistencies was assessed. The VDQ score ranges from 0 (best) to 23 (worst). A higher score for either subscore means a worse outcome. Negative change from baseline represents a worsening in quality of life for the total score or subscore. Population used are those who entered Part 1 - Induction. The number of participants analyzed for each timepoint reflect the actual number of participants with data at that timepoint. Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect change from baseline.
Time frame: Weeks 12, 26 and 52
Population: Full Analysis Set Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| APT-1011 1.5 mg HS | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores | VDQ Score Week 12 Change from Baseline | -3.9 units on a scale | Standard Deviation 6.53 |
| APT-1011 1.5 mg HS | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores | VDQ Score Week 26 Change from Baseline | -3.1 units on a scale | Standard Deviation 4.36 |
| APT-1011 1.5 mg HS | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores | VDQ Score Week 52 Change from Baseline | -9.4 units on a scale | Standard Deviation 9.5 |
| APT-1011 1.5 mg HS | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores | AMS Score Week 12 Change from Baseline | 0.0 units on a scale | Standard Deviation 0 |
| APT-1011 1.5 mg HS | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores | AMS Score Week 26 Change from Baseline | 0.0 units on a scale | Standard Deviation 0 |
| APT-1011 1.5 mg HS | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores | AMS Score Week 52 Change from Baseline | 0.0 units on a scale | Standard Deviation 0 |
| APT-1011 1.5 mg BID | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores | AMS Score Week 26 Change from Baseline | -2.2 units on a scale | Standard Deviation 8.31 |
| APT-1011 1.5 mg BID | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores | AMS Score Week 52 Change from Baseline | -3.5 units on a scale | Standard Deviation 8.39 |
| APT-1011 1.5 mg BID | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores | AMS Score Week 12 Change from Baseline | -3.0 units on a scale | Standard Deviation 7.8 |
| APT-1011 1.5 mg BID | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores | VDQ Score Week 12 Change from Baseline | -2.5 units on a scale | Standard Deviation 3.24 |
| APT-1011 1.5 mg BID | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores | VDQ Score Week 52 Change from Baseline | -9.4 units on a scale | Standard Deviation 8.25 |
| APT-1011 1.5 mg BID | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores | VDQ Score Week 26 Change from Baseline | -6.8 units on a scale | Standard Deviation 7.03 |
| APT-1011 3 mg HS | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores | VDQ Score Week 26 Change from Baseline | -6.8 units on a scale | Standard Deviation 6.46 |
| APT-1011 3 mg HS | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores | AMS Score Week 26 Change from Baseline | -0.7 units on a scale | Standard Deviation 4.44 |
| APT-1011 3 mg HS | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores | VDQ Score Week 12 Change from Baseline | -5.0 units on a scale | Standard Deviation 6 |
| APT-1011 3 mg HS | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores | VDQ Score Week 52 Change from Baseline | -12.6 units on a scale | Standard Deviation 9.67 |
| APT-1011 3 mg HS | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores | AMS Score Week 52 Change from Baseline | -0.8 units on a scale | Standard Deviation 2.71 |
| APT-1011 3 mg HS | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores | AMS Score Week 12 Change from Baseline | -1.4 units on a scale | Standard Deviation 3.3 |
| APT-1011 3 mg BID | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores | AMS Score Week 26 Change from Baseline | -3.3 units on a scale | Standard Deviation 7.54 |
| APT-1011 3 mg BID | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores | VDQ Score Week 26 Change from Baseline | -7.7 units on a scale | Standard Deviation 9.47 |
| APT-1011 3 mg BID | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores | AMS Score Week 52 Change from Baseline | -2.6 units on a scale | Standard Deviation 7.17 |
| APT-1011 3 mg BID | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores | VDQ Score Week 52 Change from Baseline | -9.6 units on a scale | Standard Deviation 7.27 |
| APT-1011 3 mg BID | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores | AMS Score Week 12 Change from Baseline | -1.3 units on a scale | Standard Deviation 6.47 |
| APT-1011 3 mg BID | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores | VDQ Score Week 12 Change from Baseline | -4.1 units on a scale | Standard Deviation 8.03 |
| Placebo BID | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores | VDQ Score Week 12 Change from Baseline | -2.7 units on a scale | Standard Deviation 3.41 |
| Placebo BID | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Subscores | AMS Score Week 12 Change from Baseline | 1.5 units on a scale | Standard Deviation 6.85 |
Comparison: VDQ Score Change from Baseline Week 12p-value: 0.45990% CI: [-3.49, 3.08]ANCOVA
Comparison: VDQ Score Change from Baseline Week 12p-value: 0.61790% CI: [-2.65, 3.8]ANCOVA
Comparison: VDQ Score Change from Baseline Week 12p-value: 0.16790% CI: [-5.07, 1.33]ANCOVA
Comparison: VDQ Score Change from Baseline Week 12p-value: 0.37390% CI: [-3.88, 2.61]ANCOVA
Comparison: AMS Score Change from Baseline Week 12p-value: 0.20390% CI: [-4.96, 1.64]ANCOVA
Comparison: AMS Score Change from Baseline Week 12p-value: 0.01490% CI: [-7.54, -1.13]ANCOVA
Comparison: AMS Score Change from Baseline Week 12p-value: 0.06190% CI: [-6.23, 0.2]ANCOVA
Comparison: AMS Score Change from Baseline Week 12p-value: 0.09790% CI: [-5.83, 0.69]ANCOVA
Secondary
Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Total Score
Change from Baseline 7-Day EEsAI total score assessed prior to randomization and those assessed at Weeks 12, 26 and 52 (Total score 100). Eosinophilic Esophagitis Activity Index Total Score: 0 (best) to 100 (worst) based on the sum of the categorized subscores for frequency of trouble swallowing \[never (0), 1-3x (15) or 4-6x (27) per week\]; duration of trouble swallowing \[≤5 min (0), \>5 min (6)\]; pain when swallowing \[no (0), yes (15)\]; Visual Dysphagia Question score \[0 (best),12,19, 21, or 23 (worst)\]; avoidance modification and slow eating score \[0 (best), 9, or 25 (worst)\]. A higher score means a worse outcome. Population used are those who entered Part 1 - Induction. The number of participants analyzed for each timepoint reflect the actual number of participants with data at that timepoint. Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect the change from baseline 7-day EEs
Time frame: Weeks 12, 26 and 52
Population: Full Analysis Set Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| APT-1011 1.5 mg HS | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Total Score | EEsAI Total Score Week 12 Change from Baseline | -20.4 units on a scale | Standard Deviation 15.9 |
| APT-1011 1.5 mg HS | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Total Score | EEsAI Total Score Week 26 Change from Baseline | -25.6 units on a scale | Standard Deviation 21.11 |
| APT-1011 1.5 mg HS | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Total Score | EEsAI Total Score Week 52 Change from Baseline | -39.8 units on a scale | Standard Deviation 28.42 |
| APT-1011 1.5 mg BID | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Total Score | EEsAI Total Score Week 26 Change from Baseline | -29.6 units on a scale | Standard Deviation 25.48 |
| APT-1011 1.5 mg BID | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Total Score | EEsAI Total Score Week 12 Change from Baseline | -15.6 units on a scale | Standard Deviation 21.02 |
| APT-1011 1.5 mg BID | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Total Score | EEsAI Total Score Week 52 Change from Baseline | -37.4 units on a scale | Standard Deviation 27.02 |
| APT-1011 3 mg HS | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Total Score | EEsAI Total Score Week 12 Change from Baseline | -22.7 units on a scale | Standard Deviation 16.6 |
| APT-1011 3 mg HS | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Total Score | EEsAI Total Score Week 26 Change from Baseline | -28.8 units on a scale | Standard Deviation 21.1 |
| APT-1011 3 mg HS | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Total Score | EEsAI Total Score Week 52 Change from Baseline | -37.0 units on a scale | Standard Deviation 23.72 |
| APT-1011 3 mg BID | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Total Score | EEsAI Total Score Week 12 Change from Baseline | -22.6 units on a scale | Standard Deviation 21.11 |
| APT-1011 3 mg BID | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Total Score | EEsAI Total Score Week 52 Change from Baseline | -41.1 units on a scale | Standard Deviation 20.56 |
| APT-1011 3 mg BID | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Total Score | EEsAI Total Score Week 26 Change from Baseline | -34.6 units on a scale | Standard Deviation 25.43 |
| Placebo BID | Change From Baseline 7-Day Eosinophilic Esophagitis Activity Index (EEsAI) Total Score | EEsAI Total Score Week 12 Change from Baseline | -9.6 units on a scale | Standard Deviation 14.07 |
Comparison: EEsAI Total Score Change from Baseline Week 12p-value: 0.07990% CI: [-19.06, 1.45]ANCOVA
Comparison: EEsAI Total Score Change from Baseline Week 12p-value: 0.19590% CI: [-15.14, 4.78]ANCOVA
Comparison: EEsAI Total Score Change from Baseline Week 12p-value: 0.0290% CI: [-22.55, -2.58]ANCOVA
Comparison: EEsAI Total Score Change from Baseline Week 12p-value: 0.04390% CI: [-20.74, -0.48]ANCOVA
Secondary
Change From Baseline Eosinophilic Esophagitis Endoscopic Reference Score (EREFs) at Week 12, 26, and 52
Endoscopic changes will be assessed as per the EREFs evaluation based on the following endoscopic features: edema \[Grade {Gr} 0 (absent) or Gr 1 (present)\], strictures \[Gr 0 (absent) or Gr 1 (present)\], rings \[Gr 0 (none), Gr 1 (mild), Gr 2 (moderate), Gr 3 (severe)\], exudates \[Gr 0 (none), Gr 1 (mild), Gr (severe)\], furrows \[Gr 0 (none), Gr 1 (mild), Gr 2 (severe)\], crepe paper esophagus \[Gr 0 (absent) or Gr 1 (present)\], narrow caliber esophagus \[Gr 0 (absent) or Gr 1 (present)\], and esophageal erosions \[Normal (0), Gr A (1), Gr B (2), Gr C (3), or Gr D (4)\]. EREFs: 0 (best) to 15 (worst) based on the sum of the subscores listed above. Population used are those who entered Part 1 - Induction. The number of participants analyzed for each timepoint reflect the actual number of participants with data at that timepoint. Note: Following Week 14, all patients in the placebo group were given APT-1011 3 mg BID and results reflect EREF evaluation following 12 or 38 weeks of treatment.
Time frame: Week 12, Week 26, and Week 52
Population: Full Analysis Set Population receiving double-blind study medication
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| APT-1011 1.5 mg HS | Change From Baseline Eosinophilic Esophagitis Endoscopic Reference Score (EREFs) at Week 12, 26, and 52 | Week 12 Change From Baseline | -2.4 units on a scale | Standard Deviation 2.04 |
| APT-1011 1.5 mg HS | Change From Baseline Eosinophilic Esophagitis Endoscopic Reference Score (EREFs) at Week 12, 26, and 52 | Week 26 Change From Baseline | -3.1 units on a scale | Standard Deviation 1.25 |
| APT-1011 1.5 mg HS | Change From Baseline Eosinophilic Esophagitis Endoscopic Reference Score (EREFs) at Week 12, 26, and 52 | Week 52 Change From Baseline | -3.4 units on a scale | Standard Deviation 1.82 |
| APT-1011 1.5 mg BID | Change From Baseline Eosinophilic Esophagitis Endoscopic Reference Score (EREFs) at Week 12, 26, and 52 | Week 26 Change From Baseline | -3.2 units on a scale | Standard Deviation 2.77 |
| APT-1011 1.5 mg BID | Change From Baseline Eosinophilic Esophagitis Endoscopic Reference Score (EREFs) at Week 12, 26, and 52 | Week 12 Change From Baseline | -2.7 units on a scale | Standard Deviation 2.66 |
| APT-1011 1.5 mg BID | Change From Baseline Eosinophilic Esophagitis Endoscopic Reference Score (EREFs) at Week 12, 26, and 52 | Week 52 Change From Baseline | -3.5 units on a scale | Standard Deviation 3.08 |
| APT-1011 3 mg HS | Change From Baseline Eosinophilic Esophagitis Endoscopic Reference Score (EREFs) at Week 12, 26, and 52 | Week 12 Change From Baseline | -3.3 units on a scale | Standard Deviation 2.36 |
| APT-1011 3 mg HS | Change From Baseline Eosinophilic Esophagitis Endoscopic Reference Score (EREFs) at Week 12, 26, and 52 | Week 26 Change From Baseline | -4.2 units on a scale | Standard Deviation 2.61 |
| APT-1011 3 mg HS | Change From Baseline Eosinophilic Esophagitis Endoscopic Reference Score (EREFs) at Week 12, 26, and 52 | Week 52 Change From Baseline | -3.8 units on a scale | Standard Deviation 3.19 |
| APT-1011 3 mg BID | Change From Baseline Eosinophilic Esophagitis Endoscopic Reference Score (EREFs) at Week 12, 26, and 52 | Week 12 Change From Baseline | -2.2 units on a scale | Standard Deviation 2.15 |
| APT-1011 3 mg BID | Change From Baseline Eosinophilic Esophagitis Endoscopic Reference Score (EREFs) at Week 12, 26, and 52 | Week 52 Change From Baseline | -2.9 units on a scale | Standard Deviation 1.29 |
| APT-1011 3 mg BID | Change From Baseline Eosinophilic Esophagitis Endoscopic Reference Score (EREFs) at Week 12, 26, and 52 | Week 26 Change From Baseline | -3.0 units on a scale | Standard Deviation 1.67 |
| Placebo BID | Change From Baseline Eosinophilic Esophagitis Endoscopic Reference Score (EREFs) at Week 12, 26, and 52 | Week 12 Change From Baseline | -0.9 units on a scale | Standard Deviation 1.62 |
Comparison: Least-squares Mean differences, 90% confidence intervals and 1-sided p-values for comparisons of each APT-1011 dose group to Placebo at Week 12 are from an ANCOVA modelp-value: 0.0290% CI: [-2.29, -0.26]ANCOVA
Comparison: Least-squares Mean differences, 90% confidence intervals and 1-sided p-values for comparisons of each APT-1011 dose group to Placebo at Week 12 are from an ANCOVA modelp-value: <0.00190% CI: [-3.07, -1.1]ANCOVA
Comparison: Least-squares Mean differences, 90% confidence intervals and 1-sided p-values for comparisons of each APT-1011 dose group to Placebo at Week 12 are from an ANCOVA modelp-value: <0.00190% CI: [-3.23, -1.26]ANCOVA
Comparison: Least-squares Mean differences, 90% confidence intervals and 1-sided p-values for comparisons of each APT-1011 dose group to Placebo at Week 12 are from an ANCOVA modelp-value: 0.00590% CI: [-2.59, -0.59]ANCOVA
Secondary
Change From Baseline Global EoE Symptom Score
Change from baseline global EOE symptom score assessed prior to randomization to scores for 7-day recall at Week 4, 8, 12, 14, 18, 22, 26, 28, 36, 44, and 52 visits. Global Eosinophilic Esophagitis Symptom Score: On a scale from 0 (no symptoms) to 10 (most severe symptoms), how severe were your EoE symptoms over the past 7 days? Patients were asked to think of all their symptoms due to EoE and make an overall statement by selecting a number. Population used are those who entered Part 1 - Induction. The number of participants analyzed for each timepoint reflect the actual number of participants with data at that timepoint. Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect change from baseline global EOE symptom score following 4, 8, 12, 14, 22, 30 or 38 weeks of treatment.
Time frame: Week 4, 8, 12, 14, 18, 22, 26, 28, 36, 44, and 52
Population: Full Analysis Set Population receiving double-blind study medication
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| APT-1011 1.5 mg HS | Change From Baseline Global EoE Symptom Score | Week 52 Change from Baseline | -3.3 units on a scale | Standard Deviation 1.71 |
| APT-1011 1.5 mg HS | Change From Baseline Global EoE Symptom Score | Week 22 Change from Baseline | -4.0 units on a scale | Standard Deviation 1.41 |
| APT-1011 1.5 mg HS | Change From Baseline Global EoE Symptom Score | Week 8 Change from Baseline | -2.6 units on a scale | Standard Deviation 2.12 |
| APT-1011 1.5 mg HS | Change From Baseline Global EoE Symptom Score | Week 28 Change from Baseline | -4.3 units on a scale | Standard Deviation 1.38 |
| APT-1011 1.5 mg HS | Change From Baseline Global EoE Symptom Score | Week 26 Change from Baseline | -3.8 units on a scale | Standard Deviation 1.39 |
| APT-1011 1.5 mg HS | Change From Baseline Global EoE Symptom Score | Week 12 Change from Baseline | -3.1 units on a scale | Standard Deviation 2.17 |
| APT-1011 1.5 mg HS | Change From Baseline Global EoE Symptom Score | Week 4 Change from Baseline | -1.8 units on a scale | Standard Deviation 2.64 |
| APT-1011 1.5 mg HS | Change From Baseline Global EoE Symptom Score | Week 44 Change from Baseline | -4.8 units on a scale | Standard Deviation 2.39 |
| APT-1011 1.5 mg HS | Change From Baseline Global EoE Symptom Score | Week 14 Change from Baseline | -2.7 units on a scale | Standard Deviation 2.26 |
| APT-1011 1.5 mg HS | Change From Baseline Global EoE Symptom Score | Week 36 Change from Baseline | -4.2 units on a scale | Standard Deviation 1.47 |
| APT-1011 1.5 mg HS | Change From Baseline Global EoE Symptom Score | Week 18 Change from Baseline | -4.1 units on a scale | Standard Deviation 1.36 |
| APT-1011 1.5 mg BID | Change From Baseline Global EoE Symptom Score | Week 18 Change from Baseline | -2.7 units on a scale | Standard Deviation 2.58 |
| APT-1011 1.5 mg BID | Change From Baseline Global EoE Symptom Score | Week 28 Change from Baseline | -3.3 units on a scale | Standard Deviation 2.42 |
| APT-1011 1.5 mg BID | Change From Baseline Global EoE Symptom Score | Week 12 Change from Baseline | -1.5 units on a scale | Standard Deviation 2.2 |
| APT-1011 1.5 mg BID | Change From Baseline Global EoE Symptom Score | Week 22 Change from Baseline | -3.2 units on a scale | Standard Deviation 2.46 |
| APT-1011 1.5 mg BID | Change From Baseline Global EoE Symptom Score | Week 14 Change from Baseline | -2.3 units on a scale | Standard Deviation 2.45 |
| APT-1011 1.5 mg BID | Change From Baseline Global EoE Symptom Score | Week 52 Change from Baseline | -3.1 units on a scale | Standard Deviation 2.4 |
| APT-1011 1.5 mg BID | Change From Baseline Global EoE Symptom Score | Week 36 Change from Baseline | -3.9 units on a scale | Standard Deviation 2.25 |
| APT-1011 1.5 mg BID | Change From Baseline Global EoE Symptom Score | Week 8 Change from Baseline | -1.7 units on a scale | Standard Deviation 1.94 |
| APT-1011 1.5 mg BID | Change From Baseline Global EoE Symptom Score | Week 4 Change from Baseline | -1.3 units on a scale | Standard Deviation 2.15 |
| APT-1011 1.5 mg BID | Change From Baseline Global EoE Symptom Score | Week 26 Change from Baseline | -3.1 units on a scale | Standard Deviation 2.52 |
| APT-1011 1.5 mg BID | Change From Baseline Global EoE Symptom Score | Week 44 Change from Baseline | -3.7 units on a scale | Standard Deviation 2.41 |
| APT-1011 3 mg HS | Change From Baseline Global EoE Symptom Score | Week 44 Change from Baseline | -4.4 units on a scale | Standard Deviation 3.2 |
| APT-1011 3 mg HS | Change From Baseline Global EoE Symptom Score | Week 4 Change from Baseline | -2.5 units on a scale | Standard Deviation 3.12 |
| APT-1011 3 mg HS | Change From Baseline Global EoE Symptom Score | Week 8 Change from Baseline | -3.1 units on a scale | Standard Deviation 2.64 |
| APT-1011 3 mg HS | Change From Baseline Global EoE Symptom Score | Week 12 Change from Baseline | -3.1 units on a scale | Standard Deviation 2.74 |
| APT-1011 3 mg HS | Change From Baseline Global EoE Symptom Score | Week 14 Change from Baseline | -3.9 units on a scale | Standard Deviation 2.81 |
| APT-1011 3 mg HS | Change From Baseline Global EoE Symptom Score | Week 18 Change from Baseline | -4.1 units on a scale | Standard Deviation 2.92 |
| APT-1011 3 mg HS | Change From Baseline Global EoE Symptom Score | Week 22 Change from Baseline | -3.8 units on a scale | Standard Deviation 2.97 |
| APT-1011 3 mg HS | Change From Baseline Global EoE Symptom Score | Week 26 Change from Baseline | -4.0 units on a scale | Standard Deviation 2.68 |
| APT-1011 3 mg HS | Change From Baseline Global EoE Symptom Score | Week 28 Change from Baseline | -4.8 units on a scale | Standard Deviation 2.44 |
| APT-1011 3 mg HS | Change From Baseline Global EoE Symptom Score | Week 36 Change from Baseline | -4.8 units on a scale | Standard Deviation 2.09 |
| APT-1011 3 mg HS | Change From Baseline Global EoE Symptom Score | Week 52 Change from Baseline | -4.2 units on a scale | Standard Deviation 2.66 |
| APT-1011 3 mg BID | Change From Baseline Global EoE Symptom Score | Week 4 Change from Baseline | -1.6 units on a scale | Standard Deviation 1.39 |
| APT-1011 3 mg BID | Change From Baseline Global EoE Symptom Score | Week 28 Change from Baseline | -3.9 units on a scale | Standard Deviation 2.09 |
| APT-1011 3 mg BID | Change From Baseline Global EoE Symptom Score | Week 14 Change from Baseline | -2.8 units on a scale | Standard Deviation 1.77 |
| APT-1011 3 mg BID | Change From Baseline Global EoE Symptom Score | Week 26 Change from Baseline | -3.8 units on a scale | Standard Deviation 2.57 |
| APT-1011 3 mg BID | Change From Baseline Global EoE Symptom Score | Week 22 Change from Baseline | -3.0 units on a scale | Standard Deviation 2.76 |
| APT-1011 3 mg BID | Change From Baseline Global EoE Symptom Score | Week 18 Change from Baseline | -3.1 units on a scale | Standard Deviation 2.17 |
| APT-1011 3 mg BID | Change From Baseline Global EoE Symptom Score | Week 52 Change from Baseline | -4.7 units on a scale | Standard Deviation 2.27 |
| APT-1011 3 mg BID | Change From Baseline Global EoE Symptom Score | Week 36 Change from Baseline | -3.9 units on a scale | Standard Deviation 2.07 |
| APT-1011 3 mg BID | Change From Baseline Global EoE Symptom Score | Week 12 Change from Baseline | -1.7 units on a scale | Standard Deviation 2.42 |
| APT-1011 3 mg BID | Change From Baseline Global EoE Symptom Score | Week 8 Change from Baseline | -2.1 units on a scale | Standard Deviation 1.92 |
| APT-1011 3 mg BID | Change From Baseline Global EoE Symptom Score | Week 44 Change from Baseline | -4.4 units on a scale | Standard Deviation 1.95 |
| Placebo BID | Change From Baseline Global EoE Symptom Score | Week 12 Change from Baseline | -1.7 units on a scale | Standard Deviation 1.83 |
| Placebo BID | Change From Baseline Global EoE Symptom Score | Week 4 Change from Baseline | -1.0 units on a scale | Standard Deviation 1.67 |
| Placebo BID | Change From Baseline Global EoE Symptom Score | Week 8 Change from Baseline | -1.4 units on a scale | Standard Deviation 2.21 |
Comparison: Least-squares Mean differences, 90% confidence intervals and 1-sided p-values for comparison of each APT-1011 dose group to placebo at Week 12 are from an ANCOVA model.p-value: 0.06790% CI: [-2.49, 0.12]ANCOVA
Comparison: Least-squares Mean differences, 90% confidence intervals and 1-sided p-values for comparison of each APT-1011 dose group to placebo at Week 12 are from an ANCOVA model.p-value: 0.67290% CI: [-0.91, 1.59]ANCOVA
Comparison: Least-squares Mean differences, 90% confidence intervals and 1-sided p-values for comparison of each APT-1011 dose group to placebo at Week 12 are from an ANCOVA model.p-value: 0.04890% CI: [-2.55, -0.01]ANCOVA
Comparison: Least-squares Mean differences, 90% confidence intervals and 1-sided p-values for comparison of each APT-1011 dose group to placebo at Week 12 are from an ANCOVA model.p-value: 0.65390% CI: [-0.98, 1.59]ANCOVA
Secondary
Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit
Change From Baseline PGIC for EoE Symptoms as Assessed Prior to Randomization at Weeks 4, 8, 12, 14, 18, 22, 26, 28, 36, 44, and 52. Population used are those who entered Part 1 - Induction. The number of participants analyzed for each timepoint reflect the actual number of participants with data at that timepoint. Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect change from baseline PGIC for EoE symptoms following 4, 8, 12, 14, 22, 30 or 38 weeks of treatment.
Time frame: Weeks 4, 8, 12, 14, 18, 22, 26, 36, 44, and 52
Population: Full Analysis Set
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Stayed the Same | 4 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Stayed the Same | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderately Improved | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Much Improved | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderately Improved | 5 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Much Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Stayed the Same | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | A Little Improved | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | A Little Improved | 3 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Stayed the Same | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | A Little Improved | 6 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Stayed the Same | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Much Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Much Improved | 6 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderately Improved | 5 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | A Little Improved | 9 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | A Little Improved | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Much Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Much Improved | 3 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderately Improved | 4 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderately Improved | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | A Little Improved | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Stayed the Same | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Much Improved | 3 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Much Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Much Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Much Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Stayed the Same | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Much Improved | 4 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderately Improved | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | A Little Improved | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Stayed the Same | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | A Little Worse | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Much Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Much Improved | 4 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderately Improved | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Stayed the Same | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | A Little Worse | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | A Little Improved | 3 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Stayed the Same | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | A Little Improved | 4 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Much Improved | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Much Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Much Improved | 4 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderately Improved | 7 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Much Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderately Improved | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | A Little Improved | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Stayed the Same | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Much Improved | 3 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Much Improved | 3 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Much Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Much Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderately Improved | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Much Improved | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderately Improved | 6 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | A Little Improved | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | A Little Improved | 4 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Much Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Stayed the Same | 4 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | A Little Improved | 9 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderately Improved | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Much Improved | 4 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Much Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Stayed the Same | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | A Little Improved | 9 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderately Improved | 4 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Much Improved | 6 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Much Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Stayed the Same | 4 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | A Little Improved | 5 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderately Improved | 5 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Much Improved | 8 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Much Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Stayed the Same | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderately Improved | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Much Improved | 8 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Much Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | A Little Worse | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Stayed the Same | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | A Little Improved | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderately Improved | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Much Improved | 11 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Much Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Stayed the Same | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | A Little Improved | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderately Improved | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Much Improved | 11 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Much Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Stayed the Same | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | A Little Improved | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderately Improved | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Much Improved | 13 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Much Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Stayed the Same | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | A Little Improved | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderately Improved | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Much Improved | 11 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Much Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Stayed the Same | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | A Little Improved | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderately Improved | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Much Improved | 14 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Much Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Stayed the Same | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | A Little Improved | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderately Improved | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Much Improved | 12 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Much Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Stayed the Same | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | A Little Improved | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderately Improved | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Much Improved | 10 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Stayed the Same | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Much Improved | 6 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Much Improved | 7 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderately Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | A Little Improved | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Stayed the Same | 4 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Much Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderately Improved | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderately Improved | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | A Little Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Much Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderately Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Much Improved | 8 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | A Little Improved | 5 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | A Little Worse | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderately Improved | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Much Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderately Worse | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Stayed the Same | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | A Little Worse | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderately Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Stayed the Same | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Much Improved | 5 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | A Little Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | A Little Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | A Little Improved | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderately Improved | 3 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | A Little Worse | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Stayed the Same | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Stayed the Same | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Much Worse | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Stayed the Same | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | A Little Improved | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderately Improved | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderately Improved | 6 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderately Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderately Improved | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Stayed the Same | 3 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | A Little Improved | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Much Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Much Improved | 10 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | A Little Improved | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderately Improved | 4 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | A Little Improved | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Stayed the Same | 4 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Stayed the Same | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | A Little Improved | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Much Improved | 9 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderately Worse | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | A Little Improved | 4 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Much Improved | 8 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Stayed the Same | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Much Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderately Improved | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | A Little Improved | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Much Worse | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderately Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Much Improved | 10 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | A Little Worse | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderately Improved | 4 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Much Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Much Improved | 9 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderately Improved | 3 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | A Little Worse | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | A Little Worse | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Much Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderately Worse | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Much Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Much Improved | 8 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderately Worse | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | A Little Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderately Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Much Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | A Little Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Much Improved | 7 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderately Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | A Little Improved | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | A Little Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderately Improved | 3 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Much Improved | 11 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Much Improved | 6 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Much Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Much Improved | 4 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Stayed the Same | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderately Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | A Little Worse | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Stayed the Same | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderately Improved | 6 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | A Little Improved | 5 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | A Little Improved | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderately Improved | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Much Improved | 8 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | A Little Improved | 7 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | A Little Improved | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Much Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderately Worse | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderately Improved | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | A Little Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Stayed the Same | 3 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | A Little Worse | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Stayed the Same | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Much Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | A Little Improved | 4 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderately Improved | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | A Little Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Much Improved | 10 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Much Improved | 10 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Much Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderately Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderately Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | A Little Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Much Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Stayed the Same | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | A Little Improved | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Much Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderately Improved | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Much Improved | 10 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderately Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Much Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Much Improved | 3 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderately Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderately Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderately Improved | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | A Little Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Stayed the Same | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderately Improved | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Stayed the Same | 3 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | A Little Improved | 3 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderately Improved | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Much Improved | 9 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderately Improved | 3 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | A Little Improved | 10 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Much Improved | 5 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | A Little Improved | 6 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Much Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderately Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Much Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | A Little Worse | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Stayed the Same | 3 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Stayed the Same | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | A Little Improved | 5 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | A Little Worse | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Stayed the Same | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderately Improved | 3 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Much Improved | 5 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderately Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Much Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderately Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderately Worse | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | A Little Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Stayed the Same | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | A Little Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | A Little Improved | 4 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Much Worse | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Much Worse | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | A Little Worse | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderately Worse | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | A Little Improved | 6 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Stayed the Same | 4 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderately Worse | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Stayed the Same | 6 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Much Improved | 2 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | A Little Improved | 2 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | A Little Worse | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderately Improved | 8 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | A Little Worse | 1 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | A Little Improved | 4 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderately Improved | 5 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Much Improved | 2 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Much Worse | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderately Improved | 4 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Stayed the Same | 3 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Much Improved | 1 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderately Worse | 1 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Change (PGIC) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Much Worse | 0 Participants |
Secondary
Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit
Change From Baseline PGIS for EoE Symptoms as Assessed Prior to Randomization at Weeks 4, 8, 12, 14, 18, 22, 26, 28, 36, 44, and 52. Population used are those who entered Part 1 - Induction. The number of participants analyzed for each timepoint reflect the actual number of participants with data at that timepoint. Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect change from baseline global EOE symptoms following 4, 8, 12, 14, 22, 30 or 38 weeks of treatment.
Time frame: Weeks 4, 8, 12, 14, 18, 22, 26, 28, 36, 44, and 52
Population: Full Analysis Set
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Moderate | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Very Severe | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Mild | 3 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Mild | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Moderate | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Mild | 3 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Moderate | 5 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Mild | 8 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Severe | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Mild | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to None | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Moderate | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Moderate | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Mild | 3 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Mild | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Mild | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Moderate | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Moderate | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Mild | 6 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Mild | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Very Severe | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Mild | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Mild | 7 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Mild | 4 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Moderate | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Mild | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Moderate | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Mild | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Mild | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Mild | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to None | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Moderate | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Mild | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Mild | 10 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to None | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Mild | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Moderate | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Mild | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Severe | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Moderate | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Mild | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to None | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to None | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Mild | 6 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Moderate | 3 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to None | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Mild | 8 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to None | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to None | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to None | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Mild | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Mild | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Moderate | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to None | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Mild | 7 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Moderate | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to None | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Mild | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Moderate | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to None | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Mild | 7 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Moderate | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to None | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Mild | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to None | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Mild | 8 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Moderate | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to None | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Mild | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to None | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Mild | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Moderate | 4 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to None | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Mild | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Mild | 7 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Moderate | 5 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Mild | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Moderate | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Severe | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to None | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Mild | 6 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Moderate | 6 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Mild | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Moderate | 6 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Severe | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Mild | 7 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Moderate | 5 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Mild | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Moderate | 4 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Severe | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to None | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Mild | 8 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Moderate | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to None | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Mild | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Moderate | 5 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to None | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Mild | 9 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Moderate | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to None | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Mild | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Moderate | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to None | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Mild | 8 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Moderate | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to None | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Mild | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Moderate | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Severe | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to None | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Mild | 8 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Moderate | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to None | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to None | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Moderate | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Very Severe | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to None | 5 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Moderate | 4 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Moderate | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to None | 5 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Moderate | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Moderate | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Mild | 5 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to None | 4 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Mild | 3 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Very Severe | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Moderate | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Moderate | 3 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Severe | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Severe | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to None | 4 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Mild | 5 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to None | 4 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to None | 3 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Moderate | 3 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to None | 5 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Mild | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Moderate | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Severe | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to None | 5 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Very Severe | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Moderate | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Mild | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to None | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Mild | 5 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Mild | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Moderate | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to None | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Moderate | 3 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Severe | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to None | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to None | 5 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to None | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to None | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Mild | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to None | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to None | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Very Severe | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to None | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Moderate | 4 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Mild | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Severe | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Mild | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to None | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to None | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Moderate | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Moderate | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Severe | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Severe | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to None | 4 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to None | 3 Participants |
| APT-1011 3 mg HS | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Moderate | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Mild | 4 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to None | 5 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to None | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Mild | 6 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Moderate | 6 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to None | 4 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to None | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Mild | 3 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Moderate | 4 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Moderate | 5 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to None | 5 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to None | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Mild | 6 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Moderate | 4 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to None | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Severe | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Moderate | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to None | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Mild | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Mild | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Moderate | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to None | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Severe | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Mild | 5 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Moderate | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Moderate | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Mild | 5 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to None | 4 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to None | 4 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Mild | 3 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Moderate | 4 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Moderate | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to None | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Mild | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Moderate | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to None | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to None | 5 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Mild | 4 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Moderate | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Moderate | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Mild | 3 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Mild | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Moderate | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to None | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Mild | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to None | 8 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Mild | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Moderate | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to None | 3 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Moderate | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Moderate | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Mild | 6 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Moderate | 7 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Severe | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Moderate | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Mild | 5 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Mild | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Mild | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Moderate | 4 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to None | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to None | 4 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to None | 1 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Very Severe | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to None | 1 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to None | 1 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Severe | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to None | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Moderate | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Moderate | 2 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Mild | 5 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Very Severe | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Mild | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to None | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Very Severe | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Moderate | 3 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Very Severe | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Severe | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Severe | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Moderate | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Severe | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Very Severe | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Severe | 3 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Severe | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Moderate | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Mild | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Moderate | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Moderate | 5 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to None | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Very Severe | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to None | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Severe | 1 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Moderate | 4 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Mild | 1 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Very Severe | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Mild | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to None | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to None | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Very Severe | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Very Severe | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to None | 1 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Mild | 1 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to None | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Severe | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Severe | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Mild | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Moderate | 3 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Mild | 6 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to None | 1 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Severe | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Moderate | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Moderate | 2 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Very Severe | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Severe | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Very Severe | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Severe | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Moderate | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Mild | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Mild | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Mild | 7 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Very Severe | 0 Participants |
| Placebo BID | Change From Baseline Patient Global Impression of Severity (PGIS) for EoE Symptoms as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Mild | 0 Participants |
Secondary
Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit
Change From Baseline PGIC of Difficulty with Food or Pills as Assessed Prior to Randomization at Weeks 4, 8, 12, 14, 18, 22, 26, 28, 36, 44, and 52. Population used are those who entered Part 1 - Induction. The number of participants analyzed for each timepoint reflect the actual number of participants with data at that timepoint. Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect change from baseline PGIC of difficulty with food or pills following 4, 8, 12, 14, 22, 30 or 38 weeks of treatment.
Time frame: Weeks 4, 8, 12, 14, 18, 22, 26, 36, 44, and 52
Population: Full Analysis Set
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderately Improved | 6 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Much Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderately Improved | 6 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderately Improved | 6 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Much Improved | 4 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Much Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Much Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Much Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | A Little Improved | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Stayed the Same | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Much Improved | 4 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderately Improved | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Much Improved | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | A Little Improved | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | A Little Improved | 5 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Stayed the Same | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Stayed the Same | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderately Improved | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderately Improved | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Much Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Much Improved | 3 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | A Little Worse | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Much Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderately Improved | 6 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | A Little Improved | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | A Little Improved | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderately Improved | 4 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Stayed the Same | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Stayed the Same | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Stayed the Same | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Much Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | A Little Improved | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Much Improved | 6 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Stayed the Same | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Much Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderately Improved | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Much Improved | 3 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Much Improved | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Much Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | A Little Improved | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | A Little Improved | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Much Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | A Little Improved | 8 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Stayed the Same | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderately Improved | 4 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Much Improved | 4 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderately Improved | 3 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | A Little Improved | 3 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | A Little Improved | 3 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | A Little Worse | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Much Improved | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Much Worse | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Stayed the Same | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Much Improved | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Stayed the Same | 4 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Much Improved | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Stayed the Same | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | A Little Improved | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | A Little Improved | 10 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderately Improved | 5 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | A Little Improved | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Much Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Much Improved | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Much Improved | 9 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Much Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderately Improved | 4 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | A Little Improved | 5 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderately Improved | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Stayed the Same | 4 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Stayed the Same | 5 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | A Little Improved | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | A Little Improved | 5 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderately Improved | 4 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Much Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Much Improved | 8 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Much Improved | 11 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | A Little Worse | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Much Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Much Improved | 9 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderately Improved | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Much Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Stayed the Same | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | A Little Improved | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Much Improved | 9 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderately Improved | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Much Improved | 12 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Much Improved | 12 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderately Improved | 4 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Much Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Much Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderately Improved | 5 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | A Little Improved | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Stayed the Same | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Much Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Stayed the Same | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderately Improved | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | A Little Worse | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Much Improved | 13 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Much Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Stayed the Same | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | A Little Worse | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | A Little Improved | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Much Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Stayed the Same | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | A Little Improved | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Much Improved | 8 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderately Improved | 5 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Much Improved | 8 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderately Improved | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Much Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | A Little Improved | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderately Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Stayed the Same | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Stayed the Same | 4 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | A Little Worse | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Stayed the Same | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Stayed the Same | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderately Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderately Worse | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | A Little Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Stayed the Same | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | A Little Improved | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderately Improved | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Much Improved | 9 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Much Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderately Worse | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | A Little Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Stayed the Same | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | A Little Improved | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderately Improved | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Much Improved | 8 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Much Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderately Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | A Little Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Stayed the Same | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | A Little Improved | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderately Improved | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Much Improved | 10 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Much Worse | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderately Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | A Little Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Stayed the Same | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | A Little Improved | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderately Improved | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Much Improved | 8 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Much Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderately Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | A Little Worse | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Stayed the Same | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | A Little Improved | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderately Improved | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Much Improved | 8 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Much Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderately Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | A Little Worse | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Stayed the Same | 4 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | A Little Improved | 4 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderately Improved | 4 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Much Improved | 6 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Much Worse | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderately Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | A Little Worse | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Stayed the Same | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | A Little Improved | 5 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderately Improved | 3 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Much Improved | 8 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Much Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderately Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | A Little Worse | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Stayed the Same | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | A Little Improved | 5 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderately Improved | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Much Improved | 9 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Much Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | A Little Worse | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Stayed the Same | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | A Little Improved | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderately Improved | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Much Improved | 8 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Much Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderately Worse | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | A Little Worse | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Stayed the Same | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | A Little Improved | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderately Improved | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Much Improved | 9 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Much Worse | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderately Worse | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | A Little Worse | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Stayed the Same | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | A Little Improved | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderately Improved | 3 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Much Improved | 7 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Much Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderately Improved | 7 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Much Improved | 9 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderately Improved | 3 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Stayed the Same | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | A Little Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | A Little Improved | 3 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Much Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderately Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Much Improved | 4 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Much Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Much Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Much Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | A Little Improved | 5 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Much Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderately Worse | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Stayed the Same | 4 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderately Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | A Little Worse | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | A Little Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Much Improved | 9 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Stayed the Same | 3 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderately Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderately Improved | 4 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | A Little Improved | 5 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Much Improved | 3 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | A Little Worse | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Much Improved | 6 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderately Improved | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | A Little Improved | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Much Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | A Little Improved | 9 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderately Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Stayed the Same | 5 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Stayed the Same | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | A Little Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | A Little Worse | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Stayed the Same | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Stayed the Same | 3 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderately Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Stayed the Same | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | A Little Improved | 4 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Much Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Much Improved | 9 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | A Little Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderately Improved | 3 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderately Improved | 3 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | A Little Improved | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderately Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Much Improved | 5 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Stayed the Same | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | A Little Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | A Little Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Much Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderately Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Much Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | A Little Improved | 5 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderately Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Much Improved | 10 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderately Improved | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Much Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | A Little Worse | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | A Little Improved | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Stayed the Same | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Much Improved | 10 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Stayed the Same | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | A Little Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderately Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderately Worse | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | A Little Improved | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Much Worse | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Much Improved | 9 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderately Improved | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderately Improved | 4 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderately Improved | 3 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | A Little Improved | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderately Improved | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Much Improved | 7 Participants |
| Placebo BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderately Improved | 6 Participants |
| Placebo BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Much Improved | 1 Participants |
| Placebo BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Much Worse | 0 Participants |
| Placebo BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | A Little Improved | 6 Participants |
| Placebo BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Much Worse | 0 Participants |
| Placebo BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Much Improved | 2 Participants |
| Placebo BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderately Improved | 2 Participants |
| Placebo BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Stayed the Same | 3 Participants |
| Placebo BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Much Worse | 0 Participants |
| Placebo BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | A Little Improved | 5 Participants |
| Placebo BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | A Little Improved | 7 Participants |
| Placebo BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | A Little Worse | 0 Participants |
| Placebo BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Stayed the Same | 5 Participants |
| Placebo BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | A Little Worse | 1 Participants |
| Placebo BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderately Worse | 0 Participants |
| Placebo BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | A Little Worse | 1 Participants |
| Placebo BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderately Worse | 0 Participants |
| Placebo BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Stayed the Same | 4 Participants |
| Placebo BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Much Improved | 1 Participants |
| Placebo BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderately Worse | 0 Participants |
| Placebo BID | Change From Baseline PGIC of Difficulty With Food or Pills as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderately Improved | 5 Participants |
Secondary
Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit
Change From Baseline PGIS for Difficulty with Food or Pills Going Down as Assessed Prior to Randomization at Weeks 4, 8, 12, 14, 18, 22, 26, 28, 36, 44, and 52. Population used are those who entered Part 1 - Induction. The number of participants analyzed for each timepoint reflect the actual number of participants with data at that timepoint. Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect change from baseline PGIS for difficulty with food or pills going down following 4, 8, 12, 14, 22, 30 or 38 weeks of treatment.
Time frame: Weeks 4, 8, 12, 14, 18, 22, 26, 28, 36, 44, and 52
Population: Full Analysis Set
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to None | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Mild | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Mild | 8 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Mild | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Moderate | 5 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Mild | 7 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Moderate | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Very Severe | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Mild | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Severe | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to None | 4 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to None | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Mild | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Severe | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Moderate | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Mild | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Mild | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to None | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Moderate | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to None | 3 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Mild | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Mild | 4 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Moderate | 3 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Mild | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to None | 3 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to None | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Severe | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Mild | 8 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Mild | 3 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Moderate | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Mild | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to None | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Moderate | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Mild | 6 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Mild | 6 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Moderate | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to None | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to None | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Moderate | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Moderate | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to None | 3 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Mild | 3 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Moderate | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Mild | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to None | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Very Severe | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to None | 2 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Mild | 1 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Mild | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Mild | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Mild | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to None | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Mild | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Moderate | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Mild | 7 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Moderate | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Mild | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to None | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Mild | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Moderate | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Mild | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Moderate | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to None | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Mild | 6 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Severe | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to None | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Mild | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Moderate | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to None | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Mild | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to None | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Severe | 4 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Mild | 7 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Moderate | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Severe | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Moderate | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to None | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Mild | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Mild | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Moderate | 4 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to None | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to None | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Moderate | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Mild | 7 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Mild | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Mild | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to None | 4 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Moderate | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to None | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Mild | 5 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Mild | 5 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Mild | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to None | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Moderate | 6 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Moderate | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Mild | 6 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Mild | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Mild | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Moderate | 7 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Mild | 4 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Moderate | 4 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Mild | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Moderate | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Mild | 7 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Severe | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Mild | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Moderate | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Mild | 5 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Mild | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Moderate | 6 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to None | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Mild | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Mild | 4 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Moderate | 3 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Severe | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to None | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Mild | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Mild | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Moderate | 2 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Moderate | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Mild | 7 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to None | 1 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Very Severe | 0 Participants |
| APT-1011 1.5 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Moderate | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Moderate | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to None | 6 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Mild | 4 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Moderate | 4 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to None | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Moderate | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Very Severe | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Mild | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to None | 4 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Mild | 5 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Moderate | 4 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to None | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Severe | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Very Severe | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Mild | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to None | 5 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Mild | 6 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Moderate | 3 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to None | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Moderate | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Severe | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to None | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to None | 4 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Mild | 3 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Moderate | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Mild | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Moderate | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Severe | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to None | 5 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Mild | 3 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Moderate | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to None | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Moderate | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Severe | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to None | 3 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Mild | 3 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Moderate | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to None | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Severe | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to None | 4 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to None | 5 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to None | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Very Severe | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to None | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Moderate | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Moderate | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Severe | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to None | 5 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to None | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Very Severe | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Very Severe | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to None | 3 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Mild | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Moderate | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to None | 2 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to None | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to None | 4 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Mild | 3 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Moderate | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to None | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Severe | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to None | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Mild | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Very Severe | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to None | 1 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg HS | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to None | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Mild | 4 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Moderate | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Mild | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Severe to None | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to None | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to None | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to None | 6 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Mild | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to None | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Moderate | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Mild | 3 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Moderate | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Mild | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to None | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Mild | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to None | 5 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Mild | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to None | 4 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Mild | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Mild to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to None | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Moderate | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Moderate to Moderate | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Severe | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to Mild | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to None | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Mild | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to None | 4 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Moderate | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Very Severe to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Mild | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to None | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Moderate | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to Mild | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Mild | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Severe to None | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Moderate | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Moderate | 3 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to Mild | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Moderate to None | 3 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 18 | Very Severe to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to Mild | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 14 | Mild to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Mild to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to None | 4 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Mild | 3 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Moderate | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Mild | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Severe | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Moderate | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Moderate | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 22 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Mild | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to None | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Moderate | 4 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Mild to Mild | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to None | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Moderate | 5 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Mild | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Mild | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Moderate | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to None | 3 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Moderate | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 26 | Very Severe to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Mild | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to None | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to None | 4 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Mild | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Moderate | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Severe to None | 3 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 28 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Moderate | 3 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 44 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to None | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Mild | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to None | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Moderate | 4 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Mild | 7 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Moderate | 4 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Mild | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to None | 4 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Mild | 5 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Mild | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Mild | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to None | 2 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Moderate | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Moderate to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Moderate | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 52 | Moderate to Moderate | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Mild | 1 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Moderate | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to None | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 36 | Very Severe to Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Very Severe | 0 Participants |
| APT-1011 3 mg BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Very Severe | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Moderate | 2 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Moderate | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Moderate | 3 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Moderate | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Mild | 1 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Severe | 3 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Mild | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to None | 1 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to None | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Moderate | 1 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Mild | 6 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to None | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Very Severe | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to None | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Very Severe | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Very Severe | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Severe | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Moderate | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to None | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Very Severe | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Moderate | 4 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Severe | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Very Severe | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to None | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to Mild | 6 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Mild | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Severe | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Severe | 1 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Moderate to None | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Very Severe | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to None | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Moderate | 3 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Very Severe | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Mild | 1 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to Severe | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Severe | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Severe | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to Mild | 1 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Severe | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Mild | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Moderate | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to None | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Very Severe to Severe | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Severe to None | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to Mild | 1 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Moderate | 4 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Severe to Very Severe | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Moderate | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Mild to None | 2 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Very Severe | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Moderate | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Mild to None | 1 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Very Severe | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Very Severe to Mild | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Moderate to Severe | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Mild | 5 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Very Severe to Severe | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 8 | Mild to Mild | 2 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 4 | Moderate to Very Severe | 0 Participants |
| Placebo BID | Change From Baseline PGIS for Difficulty With Food or Pills Going Down as Assessed Prior to Randomization Post-Baseline Visit | Week 12 | Severe to Very Severe | 0 Participants |
Secondary
Change in the Number of Dysphagia Episodes
Change in the number of dysphagia episodes at baseline (14-day period prior to randomization) compared with the 14-day period prior to the time point of interest. Population used are those who entered Part 1 - Induction. The number of participants analyzed for each timepoint reflect the actual number of participants with data at that timepoint. Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect the change in the number of dysphagia episodes following 12 or 38 weeks of treatment.
Time frame: Week 12, Week 26 and Week 52
Population: Full Analysis Set Population receiving double-blind study medication
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| APT-1011 1.5 mg HS | Change in the Number of Dysphagia Episodes | Week 12 Change from Baseline | -8.2 change in episodes per 14-day period | Standard Deviation 5.48 |
| APT-1011 1.5 mg HS | Change in the Number of Dysphagia Episodes | Week 26 Change from Baseline | -12.8 change in episodes per 14-day period | Standard Deviation 5.65 |
| APT-1011 1.5 mg HS | Change in the Number of Dysphagia Episodes | Week 52 Change from Baseline | -11.2 change in episodes per 14-day period | Standard Deviation 5.26 |
| APT-1011 1.5 mg BID | Change in the Number of Dysphagia Episodes | Week 26 Change from Baseline | -10.0 change in episodes per 14-day period | Standard Deviation 10.97 |
| APT-1011 1.5 mg BID | Change in the Number of Dysphagia Episodes | Week 12 Change from Baseline | -4.4 change in episodes per 14-day period | Standard Deviation 9.41 |
| APT-1011 1.5 mg BID | Change in the Number of Dysphagia Episodes | Week 52 Change from Baseline | -13.0 change in episodes per 14-day period | Standard Deviation 10.79 |
| APT-1011 3 mg HS | Change in the Number of Dysphagia Episodes | Week 12 Change from Baseline | -9.3 change in episodes per 14-day period | Standard Deviation 7.37 |
| APT-1011 3 mg HS | Change in the Number of Dysphagia Episodes | Week 26 Change from Baseline | -9.8 change in episodes per 14-day period | Standard Deviation 7.82 |
| APT-1011 3 mg HS | Change in the Number of Dysphagia Episodes | Week 52 Change from Baseline | -9.5 change in episodes per 14-day period | Standard Deviation 9.66 |
| APT-1011 3 mg BID | Change in the Number of Dysphagia Episodes | Week 12 Change from Baseline | -9.1 change in episodes per 14-day period | Standard Deviation 11.01 |
| APT-1011 3 mg BID | Change in the Number of Dysphagia Episodes | Week 52 Change from Baseline | -14.5 change in episodes per 14-day period | Standard Deviation 11.68 |
| APT-1011 3 mg BID | Change in the Number of Dysphagia Episodes | Week 26 Change from Baseline | -13.4 change in episodes per 14-day period | Standard Deviation 11.78 |
| Placebo BID | Change in the Number of Dysphagia Episodes | Week 12 Change from Baseline | -5.5 change in episodes per 14-day period | Standard Deviation 7.89 |
Secondary
Percentage of Histologic Non-responders by Dose at Weeks 12, 26, and 52
Percentage of histologic non-responders by dose at Weeks 12, 26, and 52. Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect non-response following 12 or 38 weeks of treatment.
Time frame: Weeks 12, 26 and 52
Population: Full Analysis Set Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| APT-1011 1.5 mg HS | Percentage of Histologic Non-responders by Dose at Weeks 12, 26, and 52 | Week 12 | 11 Participants |
| APT-1011 1.5 mg HS | Percentage of Histologic Non-responders by Dose at Weeks 12, 26, and 52 | Week 52 | 16 Participants |
| APT-1011 1.5 mg HS | Percentage of Histologic Non-responders by Dose at Weeks 12, 26, and 52 | Week 26 | 11 Participants |
| APT-1011 1.5 mg BID | Percentage of Histologic Non-responders by Dose at Weeks 12, 26, and 52 | Week 26 | 5 Participants |
| APT-1011 1.5 mg BID | Percentage of Histologic Non-responders by Dose at Weeks 12, 26, and 52 | Week 12 | 2 Participants |
| APT-1011 1.5 mg BID | Percentage of Histologic Non-responders by Dose at Weeks 12, 26, and 52 | Week 52 | 6 Participants |
| APT-1011 3 mg HS | Percentage of Histologic Non-responders by Dose at Weeks 12, 26, and 52 | Week 26 | 7 Participants |
| APT-1011 3 mg HS | Percentage of Histologic Non-responders by Dose at Weeks 12, 26, and 52 | Week 12 | 7 Participants |
| APT-1011 3 mg HS | Percentage of Histologic Non-responders by Dose at Weeks 12, 26, and 52 | Week 52 | 10 Participants |
| APT-1011 3 mg BID | Percentage of Histologic Non-responders by Dose at Weeks 12, 26, and 52 | Week 12 | 4 Participants |
| APT-1011 3 mg BID | Percentage of Histologic Non-responders by Dose at Weeks 12, 26, and 52 | Week 52 | 8 Participants |
| APT-1011 3 mg BID | Percentage of Histologic Non-responders by Dose at Weeks 12, 26, and 52 | Week 26 | 5 Participants |
| Placebo BID | Percentage of Histologic Non-responders by Dose at Weeks 12, 26, and 52 | Week 26 | 7 Participants |
| Placebo BID | Percentage of Histologic Non-responders by Dose at Weeks 12, 26, and 52 | Week 12 | 19 Participants |
| Placebo BID | Percentage of Histologic Non-responders by Dose at Weeks 12, 26, and 52 | Week 52 | 9 Participants |
Secondary
Percentage of Subjects Requiring Emergency Endoscopic Food Dis-impaction
Percentage of subjects requiring emergency endoscopic food dis-impaction by dose before Week 14, between Week 14 and Week 28, and between Week 28 and Week 52. Note: There were no patients in the placebo group after Week 14.
Time frame: before Week 14, between Week 14 and Week 28, between Week 28 and Week 52
Population: Full Analysis Set Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| APT-1011 1.5 mg HS | Percentage of Subjects Requiring Emergency Endoscopic Food Dis-impaction | Between Week 14 and Week 28 | 0 Participants |
| APT-1011 1.5 mg HS | Percentage of Subjects Requiring Emergency Endoscopic Food Dis-impaction | Before Week 14 | 0 Participants |
| APT-1011 1.5 mg HS | Percentage of Subjects Requiring Emergency Endoscopic Food Dis-impaction | Between Week 28 and Week 52 | 0 Participants |
| APT-1011 1.5 mg BID | Percentage of Subjects Requiring Emergency Endoscopic Food Dis-impaction | Between Week 14 and Week 28 | 0 Participants |
| APT-1011 1.5 mg BID | Percentage of Subjects Requiring Emergency Endoscopic Food Dis-impaction | Before Week 14 | 0 Participants |
| APT-1011 1.5 mg BID | Percentage of Subjects Requiring Emergency Endoscopic Food Dis-impaction | Between Week 28 and Week 52 | 0 Participants |
| APT-1011 3 mg HS | Percentage of Subjects Requiring Emergency Endoscopic Food Dis-impaction | Between Week 14 and Week 28 | 0 Participants |
| APT-1011 3 mg HS | Percentage of Subjects Requiring Emergency Endoscopic Food Dis-impaction | Before Week 14 | 0 Participants |
| APT-1011 3 mg HS | Percentage of Subjects Requiring Emergency Endoscopic Food Dis-impaction | Between Week 28 and Week 52 | 0 Participants |
| APT-1011 3 mg BID | Percentage of Subjects Requiring Emergency Endoscopic Food Dis-impaction | Before Week 14 | 0 Participants |
| APT-1011 3 mg BID | Percentage of Subjects Requiring Emergency Endoscopic Food Dis-impaction | Between Week 28 and Week 52 | 0 Participants |
| APT-1011 3 mg BID | Percentage of Subjects Requiring Emergency Endoscopic Food Dis-impaction | Between Week 14 and Week 28 | 0 Participants |
| Placebo BID | Percentage of Subjects Requiring Emergency Endoscopic Food Dis-impaction | Between Week 14 and Week 28 | 0 Participants |
| Placebo BID | Percentage of Subjects Requiring Emergency Endoscopic Food Dis-impaction | Before Week 14 | 0 Participants |
| Placebo BID | Percentage of Subjects Requiring Emergency Endoscopic Food Dis-impaction | Between Week 28 and Week 52 | 0 Participants |
Secondary
Percentage of Subjects Requiring Esophageal Dilation
Percentage of subjects requiring esophageal dilation by dosing group and part of the study. Note: There were no patients in the placebo group after Week 14.
Time frame: baseline to Week 52
Population: Full Analysis Set Population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| APT-1011 1.5 mg HS | Percentage of Subjects Requiring Esophageal Dilation | 0 Participants |
| APT-1011 1.5 mg BID | Percentage of Subjects Requiring Esophageal Dilation | 0 Participants |
| APT-1011 3 mg HS | Percentage of Subjects Requiring Esophageal Dilation | 0 Participants |
| APT-1011 3 mg BID | Percentage of Subjects Requiring Esophageal Dilation | 0 Participants |
| Placebo BID | Percentage of Subjects Requiring Esophageal Dilation | 0 Participants |
Secondary
Percentage of Subjects Who Met the Primary Endpoint at Week 12 and Maintained the Primary Endpoint at Weeks 26 and 52
Percentage of subjects who entered Part 2 - Maintenance and met the primary endpoint (histology) at Week 12 and maintained the primary endpoint at Week 26 and Week 52. Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect percentage of subjects who met the primary endpoint following 12 or 38 weeks of treatment.
Time frame: Week 26, and Week 52
Population: Full Analysis Set Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| APT-1011 1.5 mg HS | Percentage of Subjects Who Met the Primary Endpoint at Week 12 and Maintained the Primary Endpoint at Weeks 26 and 52 | Week 26 Responders | 7 Participants |
| APT-1011 1.5 mg HS | Percentage of Subjects Who Met the Primary Endpoint at Week 12 and Maintained the Primary Endpoint at Weeks 26 and 52 | Week 52 Responders | 3 Participants |
| APT-1011 1.5 mg BID | Percentage of Subjects Who Met the Primary Endpoint at Week 12 and Maintained the Primary Endpoint at Weeks 26 and 52 | Week 26 Responders | 17 Participants |
| APT-1011 1.5 mg BID | Percentage of Subjects Who Met the Primary Endpoint at Week 12 and Maintained the Primary Endpoint at Weeks 26 and 52 | Week 52 Responders | 16 Participants |
| APT-1011 3 mg HS | Percentage of Subjects Who Met the Primary Endpoint at Week 12 and Maintained the Primary Endpoint at Weeks 26 and 52 | Week 26 Responders | 11 Participants |
| APT-1011 3 mg HS | Percentage of Subjects Who Met the Primary Endpoint at Week 12 and Maintained the Primary Endpoint at Weeks 26 and 52 | Week 52 Responders | 9 Participants |
| APT-1011 3 mg BID | Percentage of Subjects Who Met the Primary Endpoint at Week 12 and Maintained the Primary Endpoint at Weeks 26 and 52 | Week 26 Responders | 14 Participants |
| APT-1011 3 mg BID | Percentage of Subjects Who Met the Primary Endpoint at Week 12 and Maintained the Primary Endpoint at Weeks 26 and 52 | Week 52 Responders | 11 Participants |
| Placebo BID | Percentage of Subjects Who Met the Primary Endpoint at Week 12 and Maintained the Primary Endpoint at Weeks 26 and 52 | Week 26 Responders | 7 Participants |
| Placebo BID | Percentage of Subjects Who Met the Primary Endpoint at Week 12 and Maintained the Primary Endpoint at Weeks 26 and 52 | Week 52 Responders | 5 Participants |
| Placebo BID, APT-1011 3 mg BID (Part 2) | Percentage of Subjects Who Met the Primary Endpoint at Week 12 and Maintained the Primary Endpoint at Weeks 26 and 52 | Week 26 Responders | 12 Participants |
| Placebo BID, APT-1011 3 mg BID (Part 2) | Percentage of Subjects Who Met the Primary Endpoint at Week 12 and Maintained the Primary Endpoint at Weeks 26 and 52 | Week 52 Responders | 10 Participants |
Secondary
Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15
Percentage of subjects with a peak eosinophils/HPF \<1 and \<15 at Week 12, 26 and 52. Population used are those who entered Part 1 - Induction. The number of participants analyzed for each timepoint reflect the actual number of participants with data at that timepoint. Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect peak eosinophils/HPF following 12 or 38 weeks of treatment.
Time frame: Week 12, Week 26, and Week 52
Population: Full Analysis Set Population receiving double-blind study medication
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| APT-1011 1.5 mg HS | Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15 | Week 12 : <1/HPF | 7 Participants |
| APT-1011 1.5 mg HS | Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15 | Week 12 : <15/HPF | 12 Participants |
| APT-1011 1.5 mg HS | Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15 | Week 26 : <1/HPF | 4 Participants |
| APT-1011 1.5 mg HS | Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15 | Week 52 : <1/HPF | 1 Participants |
| APT-1011 1.5 mg HS | Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15 | Week 26 : <15/HPF | 8 Participants |
| APT-1011 1.5 mg HS | Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15 | Week 52 : <15/HPF | 3 Participants |
| APT-1011 1.5 mg BID | Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15 | Week 12 : <1/HPF | 14 Participants |
| APT-1011 1.5 mg BID | Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15 | Week 52 : <15/HPF | 17 Participants |
| APT-1011 1.5 mg BID | Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15 | Week 52 : <1/HPF | 12 Participants |
| APT-1011 1.5 mg BID | Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15 | Week 26 : <1/HPF | 15 Participants |
| APT-1011 1.5 mg BID | Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15 | Week 12 : <15/HPF | 19 Participants |
| APT-1011 1.5 mg BID | Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15 | Week 26 : <15/HPF | 18 Participants |
| APT-1011 3 mg HS | Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15 | Week 52 : <15/HPF | 10 Participants |
| APT-1011 3 mg HS | Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15 | Week 26 : <15/HPF | 12 Participants |
| APT-1011 3 mg HS | Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15 | Week 12 : <15/HPF | 15 Participants |
| APT-1011 3 mg HS | Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15 | Week 12 : <1/HPF | 12 Participants |
| APT-1011 3 mg HS | Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15 | Week 52 : <1/HPF | 7 Participants |
| APT-1011 3 mg HS | Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15 | Week 26 : <1/HPF | 9 Participants |
| APT-1011 3 mg BID | Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15 | Week 52 : <1/HPF | 10 Participants |
| APT-1011 3 mg BID | Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15 | Week 12 : <15/HPF | 16 Participants |
| APT-1011 3 mg BID | Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15 | Week 52 : <15/HPF | 12 Participants |
| APT-1011 3 mg BID | Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15 | Week 26 : <1/HPF | 13 Participants |
| APT-1011 3 mg BID | Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15 | Week 26 : <15/HPF | 14 Participants |
| APT-1011 3 mg BID | Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15 | Week 12 : <1/HPF | 15 Participants |
| Placebo BID | Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15 | Week 12 : <1/HPF | 0 Participants |
| Placebo BID | Percentage of Subjects With a Peak Eosinophils/HPF Number <1 and <15 | Week 12 : <15/HPF | 1 Participants |
Secondary
Percentage of Subjects With Mean 7-day EEsAI Total Score <20
Percentage of subjects with mean 7-day EEsAI total score \<20 to those assessed at Weeks 12, 26 and 52. Eosinophilic Esophagitis Activity Index Total Score: 0 (best) to 100 (worst) based on the sum of the categorized subscores for frequency of trouble swallowing \[never (0), 1-3x (15) or 4-6x (27) per week\]; duration of trouble swallowing \[\<= 5 min (0), \>5 min (6)\]; pain when swallowing \[no (0), yes (15)\]; Visual Dysphagia Question score \[0 (best),12,19,21, or 23 (worst)\]; avoidance modification and slow eating score \[0 (best), 9, or 25 (worst)\]. Population used are those who entered Part 1 - Induction. The number of participants analyzed for each timepoint reflect the actual number of participants with data at that timepoint. Note: Following Week 14, all patients in the placebo group were given APT-1011 3mg BID and results reflect change from baseline global EOE symptom score following 12 or 38 weeks of treatment
Time frame: Weeks 12, 26, and 52
Population: Full Analysis Set population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| APT-1011 1.5 mg HS | Percentage of Subjects With Mean 7-day EEsAI Total Score <20 | Week 12 EEsAI Total Score <20 | 4 Participants |
| APT-1011 1.5 mg HS | Percentage of Subjects With Mean 7-day EEsAI Total Score <20 | Week 26 EEsAI Total Score <20 | 3 Participants |
| APT-1011 1.5 mg HS | Percentage of Subjects With Mean 7-day EEsAI Total Score <20 | Week 52 EEsAI Total Score <20 | 3 Participants |
| APT-1011 1.5 mg BID | Percentage of Subjects With Mean 7-day EEsAI Total Score <20 | Week 26 EEsAI Total Score <20 | 5 Participants |
| APT-1011 1.5 mg BID | Percentage of Subjects With Mean 7-day EEsAI Total Score <20 | Week 12 EEsAI Total Score <20 | 1 Participants |
| APT-1011 1.5 mg BID | Percentage of Subjects With Mean 7-day EEsAI Total Score <20 | Week 52 EEsAI Total Score <20 | 7 Participants |
| APT-1011 3 mg HS | Percentage of Subjects With Mean 7-day EEsAI Total Score <20 | Week 12 EEsAI Total Score <20 | 6 Participants |
| APT-1011 3 mg HS | Percentage of Subjects With Mean 7-day EEsAI Total Score <20 | Week 26 EEsAI Total Score <20 | 7 Participants |
| APT-1011 3 mg HS | Percentage of Subjects With Mean 7-day EEsAI Total Score <20 | Week 52 EEsAI Total Score <20 | 7 Participants |
| APT-1011 3 mg BID | Percentage of Subjects With Mean 7-day EEsAI Total Score <20 | Week 12 EEsAI Total Score <20 | 5 Participants |
| APT-1011 3 mg BID | Percentage of Subjects With Mean 7-day EEsAI Total Score <20 | Week 52 EEsAI Total Score <20 | 10 Participants |
| APT-1011 3 mg BID | Percentage of Subjects With Mean 7-day EEsAI Total Score <20 | Week 26 EEsAI Total Score <20 | 7 Participants |
| Placebo BID | Percentage of Subjects With Mean 7-day EEsAI Total Score <20 | Week 12 EEsAI Total Score <20 | 2 Participants |
Other Pre-specified
Number of Subjects Discontinuing Due to HPA Axis Suppression
Number of subjects discontinuing due to HPA axis suppression. Note: There were no patients in the placebo group after Week 14.
Time frame: baseline to Week 52
Population: Safety Analysis Population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| APT-1011 1.5 mg HS | Number of Subjects Discontinuing Due to HPA Axis Suppression | 0 Participants |
| APT-1011 1.5 mg BID | Number of Subjects Discontinuing Due to HPA Axis Suppression | 0 Participants |
| APT-1011 3 mg HS | Number of Subjects Discontinuing Due to HPA Axis Suppression | 0 Participants |
| APT-1011 3 mg BID | Number of Subjects Discontinuing Due to HPA Axis Suppression | 0 Participants |
| Placebo BID | Number of Subjects Discontinuing Due to HPA Axis Suppression | 0 Participants |
Other Pre-specified
Number of Subjects With Oral and Esophageal Candidiasis
Frequency of oral and esophageal candidiasis. Note: There were no patients in the placebo group after Week 14.
Time frame: baseline to Week 52
Population: Safety Analysis Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| APT-1011 1.5 mg HS | Number of Subjects With Oral and Esophageal Candidiasis | Oral candidiasis | 0 Participants |
| APT-1011 1.5 mg HS | Number of Subjects With Oral and Esophageal Candidiasis | Oesophageal candidiasis | 0 Participants |
| APT-1011 1.5 mg BID | Number of Subjects With Oral and Esophageal Candidiasis | Oesophageal candidiasis | 2 Participants |
| APT-1011 1.5 mg BID | Number of Subjects With Oral and Esophageal Candidiasis | Oral candidiasis | 3 Participants |
| APT-1011 3 mg HS | Number of Subjects With Oral and Esophageal Candidiasis | Oesophageal candidiasis | 0 Participants |
| APT-1011 3 mg HS | Number of Subjects With Oral and Esophageal Candidiasis | Oral candidiasis | 1 Participants |
| APT-1011 3 mg BID | Number of Subjects With Oral and Esophageal Candidiasis | Oral candidiasis | 3 Participants |
| APT-1011 3 mg BID | Number of Subjects With Oral and Esophageal Candidiasis | Oesophageal candidiasis | 8 Participants |
| Placebo BID | Number of Subjects With Oral and Esophageal Candidiasis | Oesophageal candidiasis | 0 Participants |
| Placebo BID | Number of Subjects With Oral and Esophageal Candidiasis | Oral candidiasis | 0 Participants |
| Placebo BID, APT-1011 3 mg BID (Part 2) | Number of Subjects With Oral and Esophageal Candidiasis | Oesophageal candidiasis | 1 Participants |
| Placebo BID, APT-1011 3 mg BID (Part 2) | Number of Subjects With Oral and Esophageal Candidiasis | Oral candidiasis | 1 Participants |
| Total APT-1011 3 mg BID | Number of Subjects With Oral and Esophageal Candidiasis | Oral candidiasis | 4 Participants |
| Total APT-1011 3 mg BID | Number of Subjects With Oral and Esophageal Candidiasis | Oesophageal candidiasis | 9 Participants |
Other Pre-specified
Number of Subjects With Treatment-Emergent Adverse Events Leading to Study Discontinuation in Part 1
Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) Leading to Study Discontinuation in Part 1.
Time frame: baseline to Week 12
Population: Safety Analysis Population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| APT-1011 1.5 mg HS | Number of Subjects With Treatment-Emergent Adverse Events Leading to Study Discontinuation in Part 1 | 0 Participants |
| APT-1011 1.5 mg BID | Number of Subjects With Treatment-Emergent Adverse Events Leading to Study Discontinuation in Part 1 | 2 Participants |
| APT-1011 3 mg HS | Number of Subjects With Treatment-Emergent Adverse Events Leading to Study Discontinuation in Part 1 | 0 Participants |
| APT-1011 3 mg BID | Number of Subjects With Treatment-Emergent Adverse Events Leading to Study Discontinuation in Part 1 | 1 Participants |
| Placebo BID | Number of Subjects With Treatment-Emergent Adverse Events Leading to Study Discontinuation in Part 1 | 2 Participants |
| Placebo BID, APT-1011 3 mg BID (Part 2) | Number of Subjects With Treatment-Emergent Adverse Events Leading to Study Discontinuation in Part 1 | 3 Participants |
Other Pre-specified
Number of Subjects With Treatment-Emergent Adverse Events Leading to Study Discontinuation in Part 2
Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) Leading to Study Discontinuation in Part 2.
Time frame: Week 12 to 52
Population: Safety Analysis Population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| APT-1011 1.5 mg HS | Number of Subjects With Treatment-Emergent Adverse Events Leading to Study Discontinuation in Part 2 | 1 Participants |
| APT-1011 1.5 mg BID | Number of Subjects With Treatment-Emergent Adverse Events Leading to Study Discontinuation in Part 2 | 0 Participants |
| APT-1011 3 mg HS | Number of Subjects With Treatment-Emergent Adverse Events Leading to Study Discontinuation in Part 2 | 0 Participants |
| APT-1011 3 mg BID | Number of Subjects With Treatment-Emergent Adverse Events Leading to Study Discontinuation in Part 2 | 0 Participants |
| Placebo BID, APT-1011 3 mg BID (Part 2) | Number of Subjects With Treatment-Emergent Adverse Events Leading to Study Discontinuation in Part 2 | 0 Participants |
| Total APT-1011 3 mg BID | Number of Subjects With Treatment-Emergent Adverse Events Leading to Study Discontinuation in Part 2 | 0 Participants |
Other Pre-specified
Percentage of Subjects With Serum Cortisol Level ≤5 μg/dL or Abnormal Adrenocorticotropic Hormone (ACTH) Stimulation Test
Percentage of subjects with serum cortisol level ≤5 μg/dL (≤138 nmol/L) or abnormal adrenocorticotropic hormone (ACTH) stimulation test (serum cortisol \<16 μg/dL \[≤440 nmol/L\] at 60 minutes). Population used are those who entered Part 2 - Maintenance. The number of participants analyzed for each timepoint reflect the actual number of participants with data at that timepoint.
Time frame: Week 12 to 52
Population: Safety Analysis Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| APT-1011 1.5 mg HS | Percentage of Subjects With Serum Cortisol Level ≤5 μg/dL or Abnormal Adrenocorticotropic Hormone (ACTH) Stimulation Test | Serum cortisol level <=5 ug/dL (<=138 mmol/L) | 4 Participants |
| APT-1011 1.5 mg HS | Percentage of Subjects With Serum Cortisol Level ≤5 μg/dL or Abnormal Adrenocorticotropic Hormone (ACTH) Stimulation Test | Abnormal ACTH stimulation test result serum cortisol level <16ug/Dl (<=440 nmol/L) | 0 Participants |
| APT-1011 1.5 mg BID | Percentage of Subjects With Serum Cortisol Level ≤5 μg/dL or Abnormal Adrenocorticotropic Hormone (ACTH) Stimulation Test | Serum cortisol level <=5 ug/dL (<=138 mmol/L) | 1 Participants |
| APT-1011 1.5 mg BID | Percentage of Subjects With Serum Cortisol Level ≤5 μg/dL or Abnormal Adrenocorticotropic Hormone (ACTH) Stimulation Test | Abnormal ACTH stimulation test result serum cortisol level <16ug/Dl (<=440 nmol/L) | 2 Participants |
| APT-1011 3 mg HS | Percentage of Subjects With Serum Cortisol Level ≤5 μg/dL or Abnormal Adrenocorticotropic Hormone (ACTH) Stimulation Test | Serum cortisol level <=5 ug/dL (<=138 mmol/L) | 4 Participants |
| APT-1011 3 mg HS | Percentage of Subjects With Serum Cortisol Level ≤5 μg/dL or Abnormal Adrenocorticotropic Hormone (ACTH) Stimulation Test | Abnormal ACTH stimulation test result serum cortisol level <16ug/Dl (<=440 nmol/L) | 1 Participants |
| APT-1011 3 mg BID | Percentage of Subjects With Serum Cortisol Level ≤5 μg/dL or Abnormal Adrenocorticotropic Hormone (ACTH) Stimulation Test | Abnormal ACTH stimulation test result serum cortisol level <16ug/Dl (<=440 nmol/L) | 4 Participants |
| APT-1011 3 mg BID | Percentage of Subjects With Serum Cortisol Level ≤5 μg/dL or Abnormal Adrenocorticotropic Hormone (ACTH) Stimulation Test | Serum cortisol level <=5 ug/dL (<=138 mmol/L) | 6 Participants |
| Placebo BID | Percentage of Subjects With Serum Cortisol Level ≤5 μg/dL or Abnormal Adrenocorticotropic Hormone (ACTH) Stimulation Test | Serum cortisol level <=5 ug/dL (<=138 mmol/L) | 0 Participants |
| Placebo BID | Percentage of Subjects With Serum Cortisol Level ≤5 μg/dL or Abnormal Adrenocorticotropic Hormone (ACTH) Stimulation Test | Abnormal ACTH stimulation test result serum cortisol level <16ug/Dl (<=440 nmol/L) | 0 Participants |